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APHPB-0020
MEASUREMENT OF STIFFNESS AND
STEATOSIS SCORE OF GRAFT BY
TRANSIENT ELASTOGRAPHY AFTER
LIVING DONOR LIVER
TRANSPLANTATION
D. J. Joo1, J. J. Lee2, S. H. Lee3, J. G. Lee1,
J. H. Lee1, J. S. Choi1, M. S. Kim1 and S. I. Kim1
1Department of Surgery, Yonsei University College of
Medicine, Seoul, Korea; 2Department of Surgery, CHA
Bundang Medical Center CHA University, Bundang,
Korea; 3Department of Surgery, Ajou University College
of Medicine, Suwon, Korea
Objectives: The aim of this study was to observe the
change of graft elasticity and steatosis measured by TE
and to analyze the correlation of liver function in
patients after LDLT.
Methods: A total of 66 LDLTs were prospectively
enrolled. Liver stiffness measure (LSM), controlled
attenuation parameter (CAP) were measured and bio-
chemical tests for pre-transplant donor and post-trans-
plant recipient at 1, 3, and 6 months.
Results: The mean age of the patients was 52.0  8.5.
There was a correlation between LSM at postoperative
1 week and pre-transplant INR (p = 0.025). LSM was
4.9  1.3 kPa in donor before transplantation, 10.0 
5.4 kPa at post-transplantation 1 week, 6.6  2.9 kPa
at post-transplantation 3 months, and 5.6  1.59 at
post-transplantation 6 months, showing significant dif-
ference chronologically. CAP was 228.2  33.93 dB/m
in donor patient before transplantation, 205.2  36.3
dB/m at post-transplantation 1 week, 214.9  43.6 dB/
m at post-transplantation 3 months, and 215.3  43.9
dB/m at post-transplantation 6 months, and only CAP
before transplantation and post-transplantation 1 week
showed significant difference. CAP at 1 week after
transplantation was correlated with recipient BMI, not
with donor BMI. The proportion of LSM F0-1 rapidly
decreased after transplantation but gradually increased
at 3 and 6 months after transplantation. In contrast, S0
was increased immediately after transplantation but
decreased chronologically.
Conclusion: TE in LDLT might be considered useful
method to assess transplanted LSM and CAP. Steatosis
level of the graft could be adapted to the recipient con-
dition within 1 week after transplantation. However
investigation to compare pathologic finding and TE
finding and prospective study is needed to confirm
diagnostic value.
APHPB-0021
IMPACT OF SERIAL CHANGE OF
DONOR SPECIFIC ANTIBODIES ON
THE GRAFT OUTCOMES AFTER LIVER
TRANSPLANTATION
J. J. Lee1, D. Joo2, J. H. Lee2, J. G. Lee2, D. H. Han2,
J. S. Choi2, S. I. Kim2 and M. S. Kim2
1Department of Surgery, CHA Bundang Medical Center
CHA University, Bundang, Korea; 2Department of
Surgery, Yonsei University College of Medicine, Seoul,
Korea
Objectives: This study aimed to investigate the acute
rejection rate and graft function after liver transplanta-
tion according to pre-transplantation donor specific
antibody (DSA) status and changing pattern of DSA
after liver transplantation.
Methods: This study was prospectively designed obser-
vational study from March 2011 to October 2013.
Forty patients were enrolled in this study. Singe antigen
bead assays were performed to detect DSA all patients
at pre-transplantation, post-transplant-7, 14, 21, 3rd
month and 6th month.
Results: There were four patients (10%) with acute
rejection and eleven patients (27.5%) with biliary com-
plication. Four patients (10%) were positive on DSA
before transplantation and one of them was converted
to negative on DSA after transplantation. Three
patients who had no DSA before transplantation
showed de Novo DSA after liver transplantation. Two
of four patients with acute rejection were positive on
DSA. One of four patients with acute rejection showed
pre-transplant DSA and de Novo DSAs were detected
in another one acute rejection patient. Seven patients
of eleven patients with biliary complication showed no
DSA and the others demonstrated de Novo DSA after
transplantation (p = 0.039). Biliary complications
occurred in two of three patients with de Novo DSA.
Figure showed the change pattern of mean fluorescent
intensity (MFI).
Conclusion: De Novo- DSA after transplantation can
be associated biliary complication and the patients with
high MFI showed more biliary complication. Further
study with large sample size and long-term follow-up
are needed.
APHPB-0030
CLINICAL IMPACT OF 18F-FDG-PET/CT
IN LIVING DONOR LIVER
TRANSPLANTATION FOR ADVANCED
HEPATOCELLULAR CARCINOMA
S. Lee, S. Kim and S. Park
Center for liver cancer, National Cancer Center,
Goyang, Korea
Objectives: The relevant number of patients with hepa-
tocellular carcinoma (HCC) beyond the Milan criteria
has undergone living donor liver transplantation
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(LDLT). However, the prognostic factors for these
patients with advanced HCC are not well established.
Methods: From March 2005 to May 2013, 280 patients
with HCC underwent LDLT in the National Cancer
Center. Among these, patients beyond the Milan criteria
were retrospectively enrolled. We analyzed the prog-
nostic significance of 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG-
PET/CT) for selecting appropriate candidates.
Results: Among total 280 patients, 147 patients
(52.5%) were confirmed to have HCC beyond the
Milan criteria using pathological reports. The patients
who met and exceeded the Milan criteria had 5-year
overall survival (OS) rates of 87.2% and 64.6%, respec-
tively, (p < 0.001) and disease-free survival (DFS) rates
of 89.8% and 56.7%, respectively (p < 0.001). In multi-
variable analysis for OS and DFS in patients beyond
the Milan criteria, PET/CT positivity [hazard ratio
(HR) 2.714, p = 0.013 for OS; HR 3.803, p < 0.001 for
DFS], total tumor size over 10 cm (HR 2.333,
p = 0.035 for OS; HR 3.334, p = 0.001 for DFS), and
microvascular invasion (HR 2.917, p = 0.025 for DFS)
were significant prognostic factors. OS In particular,
patients beyond the Milan criteria with a PET/CT-neg-
ative status and total tumor size <10 cm showed similar
OS and DFS in comparison with those within the
Milan criteria.
Conclusion: A PET/CT status in LDLT is a useful
marker to predict survival of patients with advanced
HCC.
APHPB-0031
KINETICS OF B, T, NK LYMPHOCYTES
AND ISOAGGLUTININ TITERS IN ABO
INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION USING
RITUXIMAB AND BASILIXIMAB
S. Lee, S. Kim and S. Park
Center for liver cancer, National Cancer Center,
Goyang, Korea
Objectives: The kinetics of isoagglutinin titers and lym-
phocyte subpopulations including B, T, and natural
killer (NK) cells after ABO incompatible (ABO-I)
living donor liver transplantation (LDLT) have not
been evaluated.
Methods: From January 2012 to July 2013, consecutive
ABO-I LDLT patients were enrolled at National
Cancer Center. Our desensitizing protocol included rit-
uximab, plasma exchanges, basiliximab, and intrave-
nous immune globulin without splenectomy.
Results: Twenty patients (14 males, 6 females) under-
went ABO-I LDLT due to HCC (n = 15) or liver
cirrhosis (n = 5). There was no hyperacute and anti-
body-mediated rejection. The isoagglutinin titers were
effectively lowered less than 1:16 before operation. CD
19+ B cells were rapidly eliminated after rituximab and
suppressed during 6 months postoperatively. CD 3+
and CD4+ T cells were elevated higher than CD8+ T
cells. CD4/CD8 ratio was increased during first
1 month postoperatively and decreased thereafter.
CD16+CD56+ NK cells were lowered and restored
after 4 months of LDLT. Among 15 patients with
HCC, 5 patients (33.3%) experienced early tumor
recurrence (1/8 within Milan and 4/7 beyond Milan).
Conclusion: Our protocol showed effective results in
preventing antibody-mediated rejection and suppressing
B lymphocytes. Application to advanced hepatocellular
carcinoma should be considered due to decreased natu-
ral immunity after ABO-I LDLT.
Malignant HPB Diseases
APHPB-0033
A NEW LIVER FUNCTION
EVALUATION SYSTEM: GSA BASED
QUANTITATIVE, 3-DIMENSIONAL
COMPUTERIZED IMAGING SYSTEM
Y. Mao
Liver Surgery, Peking Union Medical College Hospital
Chinese Academy of Medical Sciences, Beijing, China
Objectives: Hepatectomy remains one of the major
curative therapy options for liver tumors. Preoperative
evaluation of the remnant liver function is critical for a
safe and successful resection, yet no ideal evaluation
system is available. This study is to develop a novel
interactive analysis system (Zhong System) to predict
the risk of hepatectomy.
Methods: Current study recruited 71 pre-hepatectomy
patients and 71 healthy volunteers. A new parameter
named Uptake Index (UI) was estimated by Zhong
System. The agreement between preoperative UI values,
conventional clinical biochemistry measurements and
Child scores were evaluated. Linear regression was used
to evaluate the agreement between predicted UI for
future remnant liver (FRL) and the actual postopera-
tive UI values. Receiver operating characteristic (ROC)
curve analysis was used to evaluate the discriminative
performance UI in differentiating patient with high risk
of liver failure (Child score of 9).
Results: Preoperative UIs are highly correlated with
Child score (p < 0.0001), especially in identifying
patients with ascites and elevated bilirubin. The pre-
dicted UIs of FRL were in close agreement with the
actual post-operative UI values (r = 0.95 p < 0.001).
The ROC analysis indicated that UI values had a high
accuracy in predicting the risk of liver failure (Area
under the curve = 0.95, p < 0.0001). The best cut-off
point was 0.9 and the corresponding sensitivity was
100% and specificity was 92%.
Conclusion: Zhong System reliably estimates functional
FRL and predicts the risk of liver failure. It provides a
visual aid for liver surgeon in surgery planning and risk
assessment.
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APHPB-0049
CENTRAL HEPATECTOMY VERSUS
EXTENDED HEPATECTOMY FOR
LIVER MALIGNANCIES: A MATCHED
COHORT COMPARISON
S. Y. Lee1, E. Sadot2, J. F. Chou3, M. G€onen3, T. P.
Kingham2, P. J. Allen2, Y. Fong2, R. P. DeMatteo2,
W. R. Jarnagin2 and M. I. D’Angelica2
1Department of Hepatopancreatobiliary and Transplant
Surgery, Singapore General Hospital, Singapore,
Singapore; 2Department of Surgery, Memorial Sloan
Kettering Cancer Center, New York, NY, USA;
3Department of Epidemiology and Biostatistics,
Memorial Sloan Kettering Cancer Center, New York,
NY, USA
Objectives: Malignancies of the liver in segments 4, 5,
8 may require extended right or left hepatic resection
(EH). Central hepatectomy (CH) is an alternative ana-
tomical parenchymal preserving procedure but there
are limited data on its safely and oncological outcomes.
Methods: A review of patients undergoing liver resec-
tions for central liver malignancies in Memorial Sloan
Kettering Cancer Center was performed.A matched
case-control study (1:1) based on clinicopathological
factors (e.g. age, BMI, diagnosis, tumor size, platelets,
creatinine, INR) was performed to compare outcomes
between CH and EH.
Results: A total of 126 patients were included with a
median follow-up of 52 (CH) and 96 months (EH). CH
was associated with shorter operative time (CH:244 vs.
EH:255 min; p = 0.44), less operative blood loss
(CH:500 vs. EH:800 mls; p = 0.01) and longer total
Pringle time (CH:50 vs. 36 min; p = 0.04). There was a
trend toward lower 90-day morbidity and mortality
rates for CH as compared to EH (43% vs. 59%;
p = 0.1) (1% vs. 5%; p = 0.6), respectively. Based on
the International Study Group of Liver Surgery
(ISGLS) criteria, the incidence of post-hepatectomy
liver failure was significantly lower in the CH group
(30% vs. 14%; p < 0.03). For patients with colorectal
liver metastasis (70%; n = 44), the R0 rate and margin
width were comparable in both groups. The median
overall survival and recurrence free survival for patients
that underwent CH versus EH was 59 vs. 35 months
(p = 0.009) and 17 vs. 14 months (p = 0.1) respectively.
Conclusion: Central hepatectomy is a safe procedure
for patients with centrally located tumors and is
associated with less post-operative liver dysfunction
compared to EH.Central hepatectomy is also oncolog-
ically comparable to EH for colorectal liver metasta-
sis.
Transplantation
APHPB-0063
OUTCOMES AFTER LIVER
TRANSPLANTATION USING
MODERATE-SEVERE
MACROSTEATOTIC GRAFTS ARE
COMPARABLE WITH MILD
MACROSTEATOSIS IN A HIGH
VOLUME TRANSPLANT CENTER
A. J. Cohen1, E. K. Tan2, H. Bohorquez1, D. S.
Bruce1, I. C. Carmody1, T. W. Reichman1 and G. E.
Loss1
1Multi-Organ Transplant Center, Ochsner Health
System, New Orleans, LA, USA; 2Institute of
Translational Research, Ochsner Clinic Foundation, New
Orleans, LA, USA
Objectives: Steatotic liver grafts have been associated
with poorer long-term outcomes although recent data
suggest that they may be used safely. As the problem
of organ shortage burgeons, we evaluate the use of
macrosteatotic grafts and the outcomes after transplan-
tation.
Methods: A total of 1024 patients underwent liver
transplantation between Jul 2005 and Dec 2013. All
donor livers underwent a back-table protocol biopsy
and permanent sections were reviewed for macrosteato-
sis content. Grafts with mild (10–30%) macrosteatosis
were classified as Group 1. Moderate-severely steatotic
grafts (≥30%) were classified as Group 2. Patient
demographics, donor and operative details were analy-
sed for patient and graft survival.
Results: Seventy (6.8%) adult patients received donor
liver grafts with ≥10% macrosteatosis. There were 51
patients in Group 1 and 19 (27.1%) patients in Group
2. The most common indication for transplant was
hepatocellular carcinoma (31.4%) followed by hepatitis
C cirrhosis (27.1%). Patient and donor characteristics
were comparable between both groups. Group 2 had
slightly longer warm ischemia times (median 31 vs.
28 min, p = 0.035), higher peak AST levels (median
5148 vs. 2924 U/L, p = 0.001) and longer post-opera-
tive ICU (median 3 vs. 2 days, p = 0.017) and hospital
(median 12 vs. 8 days, p = 0.043) stays. No grafts
developed primary non-function. Comparing Groups
1 and 2, patient survival was 92.1% vs. 93.3% at
1 year and 85.9% vs. 86.2% at 5 years (p = 0.559).
Conclusion: Excellent patient and graft long-term out-
comes can be achieved even with grafts containing
≥30% macrosteatosis even though post-operative ICU
and hospital stays may be longer.
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APHPB-0079
CLINICAL APPLICATIONS OF
INDOCYANINE GREEN-FLUORESCENT
IMAGING IN LIVER SURGERY
M. Kaibori, K. Matsui, M. Ishizaki, H. Iida, T.
Sakaguchi, H. Matsushima, K. Inoue and M. Kon
Surgery, Kansai Medical University, Hirakata, Japan
Objectives: We evaluated fluorescent imaging using in-
docyanine green (ICG) to detect liver cancers and to
prevent postoperative bile leakage (PBL) by using ICG
fluorescent cholangiography as randomized clinical trial.
Methods: (1) Intravenous injection of the ICG reagent
was performed as a liver function test 1–2 weeks prior
to surgery. ICG fluorescent imaging was performed
using the Photodynamic Eye (PDE) infrared camera.
(2) 102 patients who underwent hepatic resection with-
out biliary reconstruction were divided into 2 groups.
The control group (n = 50) underwent a leak test with
ICG dye alone, and the experimental group underwent
a leak test with ICG dye, followed by ICG fluorescent
cholangiography using the PDE (n = 52).
Results: ICG fluorescent imaging was applied for liver
surgical navigation as follows: recurrent HCC after
TACE or thermal ablation therapy; colorectal meta-
static liver tumors after chemotherapy as conversion
therapy; intrahepatic cholangiocellular carcinoma. In
clinical trial of PBL, among 42 patients with fluores-
cence in the PDE group, 25 patients had insufficient
closure of bile ducts on the cut surface of the liver,
which were closed by suture or ligation. There were 5
patients who developed PBL in the control group ver-
sus no bile leakage in the PDE group.
Conclusion: ICG fluorescent imaging was useful for
liver surgical navigation including selection of the mode
of hepatic resection. ICG fluorescent cholangiography
could detect insufficiently closed bile duct stumps that
could not be identified by a standard bile leak test.
ICG fluorescent cholangiography may have useful
potential for prevention of PBL.
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APHPB-0083
SURVIVAL FOLLOWING MULTIPLE
RE-TRANSPLANTATION OF THE LIVER
IS COMPARABLE TO FIRST LIVER RE-
TRANSPLANTATION
A. J. Cohen1, E. K. Tan2, G. Therapondos1, H.
Bohorquez1, D. S. Bruce1, I. C. Carmody1, T. W.
Reichman1 and G. Loss1
1Multi-Organ Transplant Center, Ochsner Health
System, New Orleans, LA, USA; 2Institute of
Translational Research, Ochsner Clinic Foundation, New
Orleans, LA, USA
Objectives: Survival outcomes beyond first liver
re-transplantation (1Re-LTx) are not well established. We
evaluated the indications for multiple re-transplantation
(mRe-LTx) and compared outcomes with 1Re-LTx
patients.
Methods: Retrospective database and chart analyses of
patient records. Adult re-transplant (Re-LTx) patients
were divided into mRe-LTx or 1Re-LTx groups.
Patient and donor details were analyzed for patient and
graft survival.
Results: Between Jul 2005 and Dec 2013, we performed
1024 consecutive liver transplants. There were 83
(8.1%) Re-LTx including 14 (16.9%) mRe-LTx. This
included 10 2nd Re-LTx (ie. 3rd transplant), 3 3rd
Re-LTx and 1 4th Re-LTx. Eleven (13.3%) Re-LTx
were performed within 90 days of prior transplant.
Comparing mRe-LTx and 1Re-LTx, recurrent disease
was the most common indication (64.3% and 49.3%).
This comprised recurrent hepatitis C cirrhosis (55.6%
and 88.2%) and recurrent PBC/PSC (33.3% and
2.9%). There was 1 primary non-function in the
1Re-LTx group.
MRe-LTx patients were younger (median 47 vs.
54 years; p = 0.004) and had longer time-intervals
between prior and present transplant (median 47.5 vs.
26 months; p = 0.04). Both groups were otherwise simi-
lar in terms of patient and donor characteristics.
Overall patient survival using Kaplan-Meier analysis
(mRe-LTx vs. 1Re-LTx) was 85.7% vs. 82.6% at
1 year and 85.7% vs. 64.3% at 5 years (p = NS). Like-
wise, graft survival was 85.7% vs. 80.9% at 1 year and
49.0% vs. 60.7% at 5 years (p = NS).
Conclusion: We report excellent patient and graft
survival outcomes after mRe-LTx comparable to 1Re-
LTx. Superior outcomes can be achieved in highly
selected recipients at a high-volume transplant center.
Malignant HPB Diseases
APHPB-0087
PROGNOSTIC NUTRITION INDEX AND
ANATOMICAL HEPATECTOMY ARE
ASSOCIATED WITH POSTOPERATIVE
SURVIVAL OF HEPATOCELLULAR
CARCINOMA PATIENTS WITH
NORMAL PREOPERATIVE LEVELS OF
AFP AND PIVKA-II
S. Mori, M. Shimoda, T. Shiraki, Y. Iso, M. Kato and
K. Kubota
Department of Gastroenterological Surgery, Dokkyo
Medical University, Tochigi, Japan
Objectives: Although alpha-fetoprotein (AFP) and pro-
thrombin induced by vitamin K absence-II (PIVKA-II)
are valuable predictors of progression of hepatocellular
carcinoma (HCC), some patients show no increases in
these levels before surgery. Therefore, it is essential to
clarify the factors associated with the levels of these
markers for further improvement of survival.
Methods: We reviewed 648 patients who had under-
gone hepatectomy for HCC between 2000 and 2012,
and analyzed 109 patients in whom preoperative serum
AFP (≤10 ng/mL) and PIVKA-II (≤40 mAU/mL) levels
had been normal. Uni- and multivariate analyses were
performed to determine the factors associated with sur-
vival. Survival curves were compared using Kaplan-
Meier analysis and log-rank test.
Results: Univariate analysis of clinicopathological
characteristics showed that Child-Pugh class B, non-
anatomical hepatectomy (non-AH), albumin <3.5 g/dL,
a prognostic nutrition index (PNI) [10 9 albumin
© 2015 The Authors
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(g/dL) + 0.005 9 total lymphocyte count (/mm3)] of
<41, and a body mass index of <20 were significant fac-
tors affecting overall survival (OS). Multivariate analy-
sis revealed that PNI <41 and non-AH were
significantly associated with poorer OS (p < 0.001 and
p = 0.018). Kaplan-Meier analysis and log-rank test
demonstrated a significant difference in 5-year OS
between patients with PNI <41 and PNI ≥41 and
patients with non-AH and AH (9% vs. 74.8%, respec-
tively, p < 0.001; 50.1% vs. 69.5%, respectively,
p = 0.016).
Conclusion: PNI and AH are associated with postoper-
ative survival in patients with normal preoperative
AFP and PIVKA-II levels.
APHPB-0092
GLASGOW PROGNOSTIC SCORE
PREDICTS THERAPEUTIC OUTCOME
AFTER HEPATIC RESECTION FOR
HEPATOCELLULAR CARCINOMA
H. Shiba, T. Horiuchi, T. A. R. O. Sakamoto,
K. Furukawa, R. Iwase, Y. Shirai, T. Iida, Y. Fujiwara,
K. Haruki and K. Yanaga
Department of Surgery, Jikei University School of
Medicine, Tokyo, Japan
Objectives: Systemic inflammation as evidenced by the
Glasgow prognostic score (GPS) predicts cancer-specific
survival in various types of cancer. The aim of this
study was to evaluate the significance of GPS in thera-
peutic outcome after surgical resection for hepatocellu-
lar carcinoma.
Methods: The subjects were 144 patients who under-
went surgical resection for hepatocellular carcinoma.
For the assessment of systemic inflammatory response
using GPS, the patients were classified into three
groups: patients with normal serum albumin (?3.5 g/
dL) and normal serum CRP (?1.0 mg/dL) as GPS 0
(n = 76), those with low serum albumin (<3.5 g/dL) or
elevated serum CRP (>1.0 mg/dL) as GPS 1 (n = 58),
and those with low serum albumin (<3.5 g/dL) and ele-
vated serum CRP (>1.0 mg/dL) as GPS 2 (n = 10). We
retrospectively investigated the relationship between
patient characteristics including GPS, and disease-free
as well as overall survival.
Results: In disease-free survival, GPS2 (p = 0.014),
tumor number of 3 or more (p = 0.004), and positive
portal or venous invasion (p = 0.034) were independent
predictors of cancer recurrence in multivariate analysis.
In overall survival, GPS1 (p = 0.042), GPS2
(p < 0.001) and positive portal or venous invasion
(p < 0.001) were independent predictors of poor patient
outcome in multivariate analysis.
Conclusion: The GPS in patients with hepatocellular
carcinoma is an independent prognostic predictor after
hepatic resection.
APHPB-0095
CIRCULATING HEMATOPOIETIC AND
ENDOTHELIAL PROGENITOR CELLS
INDICATE THE UNFAVORABLE
TUMOR BIOLOGY IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA
W. Otto1, M. Krol2, M. Maciaszczyk3, B. Najnigier1,
W. Holowko1, J. Sierdzinski4 and M. Krawczyk1
1General Transplant & Liver Surgery, Medical
University of Warsaw, Warsaw, Poland; 2Oncology
Hematology & Internal Medicine, Medical University of
Warsaw, Warsaw, Poland; 3Surgery, Institute of
Tuberculosis Warsaw, Rabka, Poland; 4Medical
Informatics & Telemedicine, Medical University of
Warsaw, Warsaw, Poland
Objectives: Development of HCC is associated with the
process of angiogenesis and leads to the increment of
the number of stem cells in the peripheral blood circu-
lation. The objective of this study was to evaluate
whether the level of hematopoietic stem cells and endo-
thelial progenitor cells (HSCs & EPCs) could indicate
the unfavorable tumor biology and the progress of dis-
ease in HCC.
Methods: The study covered 146 HCC patients; 53
selected for liver resection, 49 for liver transplantation,
44 for palliation. Control consisted of 42 patients with
liver cirrhosis and 43 healthy individuals. The cells were
enumerated with CD45, CD34, CD133, CD309 mark-
ers. The cell rates were measured by phenotypic analy-
sis of 2 mL fresh blood in a flow cytometer. The data
were evaluated statistically.
Results: There were significant differences in the levels
of HSCs and EPCs between patients with HCC, with
liver cirrhosis and healthy volunteers (Chisq = 45.92,
p < 0.001, Chisq = 16.22, p < 0.001), as well as
between the groups of patients with HCC selected for
liver resection, liver transplantation and palliation
(Chisq = 40.86, p < 0.001, Chisq = 18.81, p < 0.001),
respectively. The multivariate analysis of regression
indicated the rates of hematopoietic stem cells and the
endothelial progenitor cells as the factor predicting
poor tumor differentiation (W = 4.2, p < 0.04 and
W = 7.11, p < 0.008).
Conclusion: Liver cirrhosis and the development of
hepatocellular carcinoma causes significant changes in
the levels of circulating hematopoietic and endothelial
progenitor cells. The cell levels correlate with the
advances of liver pathology and allow to anticipate the
unfavorable biology of the tumor
© 2015 The Authors
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APHPB-0104
A NEW FORMULA FOR CALCULATING
STANDARD LIVER VOLUME WITHOUT
USING BODY WEIGHT
T. Kokudo1, K. Hasegawa1, E. Uldry2, J. Kaneko1,
N. Akamatsu1, Y. Sakamoto1, N. Demartines2,
Y. Sugawara1, N. Kokudo1 and N. Halkic2
1Department of Surgery, Graduate School of Medicine
The University of Tokyo, Tokyo, Japan; 2Department of
Visceral Surgery, University Hospital Centre Hospitalier
Universitaire Vaudois, Lausanne, Switzerland
Objectives: The standard liver volume (SLV) is widely
used in liver surgery, especially for living donor liver
transplantation (LDLT). All the reported formulas for
SLV use body surface area or body weight, which can
be influenced strongly by the general condition of the
patient.
Methods: We analyzed the liver volumes of 180 Japa-
nese donor candidates and 50 Swiss patients with nor-
mal livers to develop a new formula. The new formula
was validated using 50 LDLT recipients and 30 patients
with colorectal liver metastases.
Results: Without using body weight-related variables,
age, body height, thoracic width measured using com-
puted tomography, and race independently predicted
the total liver volume (TLV). A new formula:
702 + (8 9 height)  (2.95 9 age) + (37.4 9 thoracic
width)  (367 9 race [1 = Asian, 0 = European]), ade-
quately predicted the TLV with a high coefficient of
determination (adjusted R2 = 0.756) compared with
other formulas. The graft volume for LDLT was corre-
lated with the postoperative prothrombin time, and the
graft volume/SLV ratio calculated using the new for-
mula was significantly better correlated with the post-
operative prothrombin time than the graft volume/SLV
ratio calculated using the other formulas or the graft
volume/body weight ratio. The new formula also pro-
vided a significantly better estimation of the remnant
liver volume of patients with colorectal liver metasta-
ses.
Conclusion: Although previously reported formulas can
accurately estimate the TLV of a healthy patient group,
the new formula was better at predicting the SLV in
the presence of a pathological condition.
Malignant HPB Diseases
APHPB-0137
ANTERIOR HEPATIC TRANSECTION
FOR CAUDATE LOBECTOMY TO
TREAT HEPATIC TUMORS SITUATED
IN OR INVOLVING THE PARACAVAL
PORTION OF THE CAUDATE LOBE
Z. Wang, S. Fu, Z. Pan, H. Liu, Y. Yang, J. Zhang,
J. Zhang and W. Zhou
3rd department of liver surgery, Eastern hepatobiliary
Surgery Hospital, Shanghai, China
Objectives: Caudate lobectomy using the anterior split
liver approach is a proper but technically demanding
operation for tumors situated in or involving the
paracaval portion of the caudate lobe. This study was
designed to share our experience in this operation.
Methods: From August 2004 to May 2014, 72 patients
received caudate lobectomy using the anterior split liver
approach in our department. The clinicopathologic and
perioperative data, complications and survival were
analyzed.
Results: The operations were successfully carried out
and there was no 30-day or 90-day perioperative mor-
tality. Seventeen patients (23.6%) received isolated cau-
date lobectomy, 13 patients (18.1%) took caudate
lobectomy plus segmentectomy IV, V, VIII and 42
patients (58.3%) received caudate lobectomy plus seg-
mentations IV. The median tumor size was 8 cm
(range, 2.4–30 cm), the operating time was 210 min
(range, 120–445 min) and the blood loss was 800 mL
(range, 200–5000 mL). The postoperative complication
rate was 34.7%. Patients in the isolated caudate lobec-
tomy group (n = 17) had more liver cirrhosis
(p < 0.001), smaller tumor size (p < 0.001), less platelet
(p < 0.001), more operating time (p = 0.046) and were
older (p = 0.018) than those in the associated resection
group (n = 55), but had no significant difference in in-
traoperative blood loss, postoperative liver function
and complications.
Conclusion: Caudate lobectomy using the anterior split
liver approach was technically feasible and safe for
patients with the tumor situated in or involving the
paracaval portion of the caudate lobe. An associated
resection with partial or whole mesohepatectomy was
preferred in patients with no or mild liver cirrhosis.
APHPB-0155
LONG NON-CODING RNA
CONTRIBUTES TO HUMAN
PANCREATIC CANCER PROGRESSION
THROUGH POSITIVE-FEEDBACK
REGULATION OF K-RAS
G. Zhao, X. Li, Q. Qin, S. C. Deng, Y. Liu, S. Zhu,
J. Y. Chen, C. Xiang, Z. He and C. Y. Wang
Pancreatic Disease Institute, Union Hospital Tongji
Medical College Huazhong University of Science and
Techn, Wuhan, China
Objectives: Recent studies indicate that long non-cod-
ing RNAs (LncRNAs) play key roles in tumorigenesis,
while its function and underlying mechanism on
progression of pancreatic cancer is far from elucidated.
The present study set out to identify the functional
dysregulated lncRNA in pancreatic cancer.
Methods: The different lncRNAs expression among
chronic pancreatitis, pancreatic cancer and paired para-
carcinoma tissues were revealed by microarray. One of
the high expressed lncRNA both in in chronic pancrea-
titis and pancreatic cancer (RP11-111E2.1-001,
lncR-RP11) was further validated in pancreatic cancer
samples, and the correlation between its expression
level and clinical characteristics including survival
data of patients was further analyzed. The effects of
lncRNA-RP11 and its potential target were assessed
both in vitro and in vivo.
Results: The data showed that the overexpressed lncR-
RP11 is significantly associated with K-ras expression
© 2015 The Authors
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and worse prognosis. Furthermore, downregulation of
lncR-RP11 significantly inhibited proliferation and
invasion of pancreatic cancer cells both in vitro and in
vivo. We further revealed that the knockdown of either
lncR-RP11 or K-ras mutually downregulated the
expression for each other. The dual luciferase reporter
assay further confirmed that both lncR-RP11 and
K-ras mRNA competitively combined with miR-3923.
Re-expressed miR-3923 significantly suppressed prolif-
eration and invasion of pancreatic cancer cells both in
vitro and in vivo, while inhibition of miR-3923 rescued
the inhibition effects of lncR-RP11 RNAi.
Conclusion: Our present study demonstrates a func-
tional LncRNA, lncR-RP11, forms positive feedback
with K-ras mRNA by acting as competitive endoge-
nous RNA (ceRNA) in pancreatic cancer. It provides
novel insights into the complicated network of
LncRNA-miRNA-mRNA interaction during tumori-
genesis.
APHPB-0167
LIGATING THE CORRESPONDING
INFLOW AND OUTFLOW VESSELS
DURING HEPATECTOMY: A
PROSPECTIVE RANDOMIZED
CONTROLLED TRIAL AND ANIMAL
STUDY
B. H. Zhang, B. X. Zhang and X. P. Chen
Surgery, Tongji Hospital Tongji Medical College Hua
Zhong University of Science and Tec, Wuhan, China
Objectives: We have devised a simple bleeding control
technique ligating the corresponding inflow and outflow
vessels without hilus dissection before the parenchyma
transection during hepatectomy. The main objective of
this study is to investigate the role of this simple tech-
nique on postoperative metastasis and survival.
Methods: During the past 10 years, 330 patients with
primary HCC were performed hepatectomy with the
new hemorrhage control technique, and prospective
randomized controlled trial was applied. Circulating
tumor cells (CTC) were detected in 24 h postopera-
tively. We further applied a mice model ligating the
pedicle of the lesion-located hepatic lobe before hepa-
tectomy to imitate the clinic practice, and evaluated the
role of the new technique on postoperative metastasis
and survival.
Results: The new technique prolonged postoperative
overall and disease-free survival for patients with
primary HCC, and reduced the number of circulating
tumor cells (CTC) postoperatively, when compared
with the conventional hepatectomy. In the animal
model, hepatectomy with the new technique showed
lower metastasis, and longer survival when compared
with conventional surgery. Human specific-AFP
expressed at a high level in the serum of the metastasis
bearing mice, but not expressed in metastasis-free
mice.
Conclusion: Ligating the inflow and outflow vessels of
the lesion-located hepatic lobe before hepatectomy
reduces postoperative metastasis and prolongs survival
of primary HCC. These results also indicate a
potential mechanism that the new technique prevents
hematogenous metastasis owing to its coincidence to
principles of oncological surgery to avoid the intraop-
erative spread of tumour cells during hepatectomy.
APHPB-0175
PERCUTANEOUS TRANSHEPATIC
BILIARY DRAINAGE COMPLICATES
POSTOPERATIVE SURVIVAL BY
SEEDING METASTASIS: AN
ONCOLOGIC EVIDENCE IN DISTAL
CHOLANGIOCARCINOMA
K. Komaya, T. Ebata, Y. Yokoyama, T. Igami,
G. Sugawara, T. Mizuno, J. Yamaguchi and M. Nagino
Surgical oncology, Nagoya University Graduate School
of Medicine, Nagoya, Japan
Objectives: Recently, a PTBD-specific disease relapse,
catheter tract recurrence, has been reported in cholan-
giocarcinoma, and this recurrence stems from cancer
cells floating in the bile. We hypothesized that PTBD
would increase the incidence of seeding recurrence.
Methods: A total of 431 patients with distal cholangio-
carcinoma who underwent pancreatoduodenectomy at
Nagoya Univ. Hospital and 29 affiliated hospitals
between 2001 and 2010 was the study cohort. Of them,
189 (44%) received PTBD and the remaining 224
patients did not (non-PTBD: endoscopic biliary drain-
age, n = 188; non-biliary drainage, n = 36). Seeding
metastasis was defined as catheter tract recurrence and
carcinomatous peritonitis/pleuritis, which were radio-
logically and/or cytologically proven.
Results: In PTBD and non-PTBD groups, tumor
relapse was found in 123 (65%) and 109 (49%)
patients, respectively (p = 0.001); seeding metastasis
accounted for 31% (n = 38) and 14% (n = 15), respec-
tively. Logistic regression analysis revealed PTBD (OR
3.54, p < 0.001) and histologic grade 2/3 (OR 2.13,
p = 0.026) as significant predictor of seeding metastasis.
Cumulative incidences of seeding metastasis at 1, 2,
and 3-years were 10%, 17%, and 21% in PTBD group;
3%, 6%, and 7% in non-PTBD group, respectively
(p < 0.001). Overall 5-year survival rates were 34% and
51% in PTBD and non-PTBD groups, respectively
(p < 0.001); Cox proportional hazard model demon-
strated that PTBD (RR 1.44, p = 0.001), R1 resection,
advanced T classification, and nodal metastasis were
independent prognostic factors.
Conclusion: PTBD deteriorates the survival by a rising
incidence of seeding metastasis. PTBD should be
avoided as far as possible in surgical candidates with
distal cholangicarcinoma.
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APHPB-0185
CENTRAL HEPATECTOMY WITH
RIGHT HEPATIC VEIN RESECTION
AND PRESERVATION OF SEGMENT 6
FOR CENTRALLY LOCATED
HEPATOCELLULAR CARCINOMA
J. F. Chuang, C. C. Yeh, M. A. Ali, T. L. Lin, C. C.
Yong, Y. W. Liu, C. C. Lin, S. H. Wang, C. C. Wang
and C. L. Chen
Division of General Surgery Department of Surgery,
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung,
Taiwan
Objectives: In order to preserve functional liver paren-
chyma, extended central hepatectomy (ECH) (segments
4, 5, 7 and 8 resection) was proposed for management
of centrally located hepatocellular carcinoma (HCC)
invading right (RHV) and middle (MHV) hepatic veins.
Segment 6 (S6) can be preserved when thick inferior
RHV (IRHV) exists. However, not every patient has
thick IRHV, so reconstruction of the outflow of S6 is
needed sometimes. Here, we discuss our surgical tech-
nique of preservation of S6.
Methods: Between July 2008 and July 2014, 7 patients
with centrally located HCC invading RHV and MHV
underwent ECH. IRHV was preserved during dissec-
tion. When cyanotic changes of S6 were noticed after
transection of RHV, S6 outflow reconstruction was
performed by using Gore-Tex graft. Data of preopera-
tive evaluations, postoperative outcomes and follow up
results were analyzed.
Results: Mean future remnant liver volume for seg-
ments 2 and 3 was 25.9  6.5% vs. 42.8  6.8% on S6
preservation. Mean diameter of tumor was
6.6  3.3 cm. Thick IRHV was found in 1 case. Out-
flow reconstruction from S6 was performed in 4 cases.
Postoperative complications included bile leak (1 case),
pleural effusion (3 cases), pneumonia (1 case) and liver
failure (1 case). Graft patency rate was 75% in
1 month. There was no perioperative mortality.
Conclusion: Preservation of S6 with/without outflow
reconstruction is a safe alternative for centrally located
HCC in selected patients with the aim of preservation
of functional liver parenchyma.
APHPB-0202
A PROPOSAL OF A NEW STAGING
SYSTEM FOR INTRAHEPATIC
CHOLANGIOCARCINOMA: ANALYSIS
OF 759 SURGICAL PATIENTS FROM A
NATIONWIDE SURVEY OF LIVER
CANCER STUDY GROUP OF JAPAN
Y. Sakamoto1, N. Kokudo1, Y. Matsuyama2, N.
Izumi3, T. Ichida4, Y. Ku5, M. Kudo6, M. Sakamoto7,
T. Takayama8, O. Nakashima9 and O. Matsui10
1Department of Surgery, The Tokyo University Hospital,
Tokyo, Japan; 2Department of Biostatistics School of
Public Health, The University of Tokyo, Tokyo, Japan;
3Department of Gastroenterology, Musashino Red Cross
Hospital, Tokyo, Japan; 4Department of
Gastroenterology, Juntendo University Shizuoka
Hospital, Tokyo, Japan; 5Division of Hepato-Biliary-
Pancreatic Surgery, Kobe University Graduate School of
Medicine, Tokyo, Japan; 6Department of
Gastroenterology and Hepatology, Kinki University
School of Medicine, Tokyo, Japan; 7Department of
Pathology, Keio University School of Medicine, Tokyo,
Japan; 8Department of Digestive Surgery, Nihon
University School of Medicine, Tokyo, Japan;
9Department of Clinical Laboratory Medicine, Kurume
University Hospital, Fukuoka, Japan; 10Department of
Radiology, anazawa University Graduate School of
Medical Science, Kanazawa, Japan
Objectives: Staging system forI ntrahepatic cholangio-
carcinoma (ICC) proposed by AJCC/UICC TNM clas-
sification 7th ed. has been fundamentally revised from
the 6th ed., excluding the tumor size and including the
periductal growth in the classification of T factor.
Methods: A total of 756 patients who underwent surgi-
cal resection between 2000 and 2005 for mass-forming
dominant ICC from Japanese nationwide database by
LCSGJ were analyzed. Of these, 419 patients with com-
plete set of valid clinicopathological factors were sub-
jects of the present study. A new T-category was
evaluated in a subgroup of 267 patients without nodal
or distant metastasis (N0M0), and stratification of the
overall survival curves was evaluated in each of the
stage.
Results: The overall survivals of the 419 patients were
best stratified with a cut-off value of 2 cm. The 5-year
survival rate of the 15 patients with ICC ≤ 2 cm with-
out nodal metastasis or vascular invasion was 100%.
Multivariate analysis showed that tumor number, nodal
metastasis and distant metastasis were independent and
significant prognostic factors. The survival curves of
N0M0 patients were well-stratified using a new T classi-
fication regulated by the 1) tumor size (≤2 cm, >2 cm),
2) tumor number and 3) vascular (portal vein) or major
biliary invasion. The survivals of patients with
T1-3N1M0 were as good as those of T4N1M0 patients,
and thereby categorized as Stage IVA, discriminating
from Stage IVB, a group of T4N1M0 or M1.
Conclusion: The current staging system of LCSGJ can
be revised to better stratify the survival curves of
patients by modifying the factors defining T category
and Staging.
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APHPB-0214
PREDICTORS OF BILE LEAKAGE
AFTER T-TUBE REMOVAL IN LIVING
DONOR LIVER TRANSPLANT
RECIPIENTS
C. Ko1, P. Lin2, K. Lin1, C. Lin1 and Y. Chen1
1Department of Surgery, Changhua Christian Hospital,
Changhua County, Taiwan; 2Transplantation Medicine
and Surgery Research Centre, Changhua Christian
Hospital, Changhua County, Taiwan
Objectives: Bile leak (BL) after T-tube removal is a fre-
quent cause of morbidity in liver transplant recipients.
The aim of this study was to determine factors that
predict the development of BL after T-tube removal in
living donor liver transplant (LDLT) recipients.
Methods: A total of 129 patients who underwent
LDLT with right lobe graft during the period January
2007 to May 2013 at a single medical center. Among
them 31 patients received biliary anastomosis with T-
tube placed were enrolled. According to abdominal
symptoms associated with signs of peritoneal irritation
after T-tube removal, patients were divided into two
sub-groups; BL and non BL group. Potential risk fac-
tors for BL after T-tube removal included preoperative
recipient-related factors, donor-related factors, opera-
tive time, and postoperative factors. Logistic regression
was used to assess possible risk factors association with
BL after T-tube removal.
Results: BL was developed in 7 (22.5%) patients after
T-tube removal. Risk factors associated with BL
included the operative time of abdominal surgery [odds
ratio (OR) = 18.6, 95% confidence interval (CI): 2.1–
24.4], the time of T-tube placement [OR = 9.7, 95%
CI: 1.2–14.7].
Conclusion: BL after T-tube removal represent a signif-
icant cause of morbidity in our LDLT recipients. Thus,
we suggest that the T-tube placement should be mini-
mized in LDLT recipients. In our study, the time of
safety for T tube placement should be longer than
8 months, especially for recipients who receive one-time
abdominal surgery.
Malignant HPB Diseases
APHPB-0226
A PHASE II STUDY OF NEOADJUVANT
CHEMORADIATION THERAPY WITH
GEMCITABINE FOR
CHOLANGIOCARCINOMA PATIENTS:
THE FIRST REPORT OF THE PRIMARY
ENDPOINT
Y. Katayose, K. Nakagawa, H. Yoshida, H. Hayashi,
T. Morikawa, T. Okada, M. Mizuma, T. Naitoh,
F. Motoi and M. Unno
Surgery, Tohoku University Graduate School, Sendai,
Japan
Objectives: To improve the prognosis of cholangio-
carcinoma patients, we have applied neoadjuvant
chemoradiation therapy followed by conventional
resection for possibly resectable cholangiocarcinoma.
Here, we analyzed and evaluated the Phase II (P-2)
study.
Methods: Patients with histologically or cytologically
confirmed adenocarcinoma of the extra- and hilar cho-
langiocarcinoma were enrolled from 2008 to 2013 at
Department Surgery, Tohoku University Hospital. The
dose of gemcitabine was determined 600 mg/m2 of
gemcitabine with external beam radiation therapy (1.8-
Gy daily fractions to a total dose of 45 Gy) (Hepato-
gastroenterology. 2011;58(112):1866–72.). The primary
endpoint of P-2 is R0-resection rate. We hypothesized
that R0-resection rate become from 60% to 80%.
Results: Total numbers of enrolled patients were 25
cases. 22 cases were operated, and 20 cases were
resected. After chemoradiation, 3 cases were not oper-
ated by liver metastases, tumor progression, and heart
failure. 2 cases were not resected by peritoneal carcino-
matosis. One case was diagnosed as pancreatic cancer
at the final pathological diagnosis. R0-resectinn cases
were 17 cases. R0 resection rate was 89.6% (17/19)
among operated cases. In recruited 24 cases (A pancre-
atic cancer was not included), R0 resection rate was
70.8% (17/24). Grade 3 and 4 adverse events (AE) were
neutropenia, leukocytopenia, and Thrombocytopenia.
No grade 5 AE and no fatal AE in this P-2 study.
Conclusion: Neoadjuvant chemoradiation therapy with
conventional resections appears to be effective and well
tolerated. We are trying to find a proper indication for
neoadjuvant therapy. After disease free survival and
overall survival are fixed, the indication will be cleared.
TRIAL REGISTRATION: UMIN Clinical Trials Reg-
istry (UMIN-CTR) UMIN UMIN000000992 and
UMIN000001754
APHPB-0230
PREOPERATIVE SERUM TOTAL
BILIRUBIN LEVEL PREDICTS
THERAPEUTIC OUTCOME AFTER
PANCREATICODUODENECTOMY FOR
PANCREATIC DUCTAL
ADENOCARCINOMA
N. Okui, H. Shiba, Y. Shirai, T. Sakamoto,
K. Furukawa, R. Iwase, T. Horiuchi, Y. Fujiwara,
K. Haruki and K. Yanaga
Surgery, Jikei University School of Medicine, Tokyo,
Japan
Objectives: Development of predictors of postoperative
complications, recurrence and prognosis is important
for operative indications and management of periopera-
tive patients. The objective of this study is to investi-
gate the relation between preoperative serum total
bilirubin level with or without biliary drainage and
long-term outcomes after pancreaticoduodenectomy
(PD) for pancreatic ductal adenocarcinoma.
Methods: The subjects were 114 patients who under-
went PD at our hospital between April 2000 and
December 2013. Of these, 9 patients were excluded,
leaving the remaining 105 patients for this study. The
following clinical variables and disease-free as well as
overall survival were evaluated: age, gender, body mass
index, diabetes, duration of operation, intraoperative
blood loss, postoperative pancreatic fistula, tumor stage
© 2015 The Authors
HPB 2015, 17 (Suppl. S2), 1–24 HPB © 2015 Americas Hepato-Pancreato-Biliary Association
Oral Abstracts 9
based on pathology, curability, preoperative biliary
drainage, and preoperative hemoglobin, total bilirubin,
albumin, C-reactive protein, CEA, and CA19-9.
Results: In disease-free and overall survival, Stage lll
or lV (p = 0.008, p = 0.003) and preoperative serum
total bilirubin (2 mg/dL or more) (p = 0.010,
p = 0.003) were independent predictors of early tumor
recurrence and death in multivariate analysis, respec-
tively. Preoperative biliary drainage were significant
predictor of early tumor recurrence and death in uni-
variate analysis (p = 0.013, p = 0.006), but not in mul-
tivariate analysis.
Conclusion: Preoperative serum total bilirubin level
may predict oncological outcome in patients with pan-
creatic ductal carcinoma after PD.
APHPB-0239
ALCOHOLISM ATTENUATING
IMPROVED SURVIVAL OUTCOMES OF
VIRAL HEPATITIS RELATED
HEPATOCELLULAR CARCINOMA: A
12-YEAR NATIONWIDE COHORT STUDY
C. C. Yeh1, J. W. Lin2, L. B. Jeng1, H. R. Yang1,
M. S. Wu3, K. N. Kuo4, Y. Y. Liu5 and C. Y. Wu5
1Department of Surgery, China Medical University
Hospital, Taichung, Taiwan; 2School of Medicine, Fu
Jen Catholic University, Taipei, Taiwan; 3Division of
Gastroenterology, National Taiwan University Hospital,
Taipei, Taiwan; 4Center for Evidence-Based Medicine,
Taipei Medical University, Taipei, Taiwan; 5Division of
Gastroenterology, Taichung Veterans General Hospital,
Taichung, Taiwan
Objectives: The influence of alcohol on viral hepatitis
related hepatocellular carcinoma (HCC) was less inves-
tigated. This study aimed to investigate serial changes
of survival outcomes in viral hepatitis related HCC
patients between 1998 and 2009 and the influence of
alcohol on these changes.
Methods: Using Taiwan’s National Health Insurance
Research Database, we investigated serial changes in
initial treatment option and survival outcomes in viral
hepatitis related HCC patients with (‘alcoholism’
group) and without alcoholism (‘non-alcoholism’
group) over three time periods (period 1: 1998–2001; 2:
2002–2005; 3: 2006–2009). Kaplan-Meir survival analy-
ses and log-rank analyses were used to determine sur-
vival outcomes. Sub-population analyses with COX
regression models were used to investigate the effect of
alcohol on risk factors that influenced survival out-
comes.
Results: Among 51,723 viral hepatitis related HCC
patients, more patients in ‘non-alcoholism’ group
received curative treatment initially in recent years
(24.6%, 26.1% and 32.2% in period 1, 2 and 3, respec-
tively, p < 0.001). For those receiving curative therapies
in ‘non-alcoholism’ group, the 5-year overall survival
increased from 50.0% (period 1) to 58.3% (period 3)
(p < 0.001); the disease-free survival advanced along
with time (Log-Rank p < 0.001); the risk of mortality
(HR, 0.81; 95% CI, 0.75–0.87, p < 0.001) and recurrent
HCC (HR, 0.90; 95% CI, 0.84–0.95, p = 0.001) also
reduced in time period 3 when compared to period 1.
However, all these advantages did not appear in ‘alco-
holism’ group.
Conclusion: To further improve survival outcomes of
viral hepatitis related HCC patients, applicable actions
to reduce alcoholism in viral hepatitis carriers should
be undertaken.
Transplantation
APHPB-0259
HEPATOCYTE TRANSPLANTATION
USING HEPATOCYTE CELL LINE
DERIVED FROM LIVER INJURY
MODER
L. Chand1, N. Shrestha1 and Y. Jeong2
1Biomedical Science, Chonbuk National University,
Jeonju, Korea; 2Research Institute of Clinical Medecine
Chonbuk National University Hospital, Chonbuk
National University, Jeonju, Korea
Objectives: Hepatocytes have very short life span and
limited capacity of replication which limits the useful-
ness of primary hepatocytes culture for research. Or-
thotropic liver Transplantation (OLT) is widely
accepted method for the treatment of many liver based
metabolic disorders but severe shortage of organ
donor, complex surgical procedure, increased mortality
of prospective organ recipient are the main limitations
of OLT. in comprision to OLT hepatocytes transplan-
tation is cost effective, less invasive, cryo-preservable
and can be distributed to multiple recipient from single
donor, so, I have hypothesized that the hepatocytes cell
line derived from liver injury model would be a promis-
ing tool from the treatment of end-stage liver disease.
Methods: For immortalised hepatocytes celll line,
8 weeks old male FVB mice fed with DDC (3-5-dieth-
oxycarbonyl-1,4-dihydrocollidine) diet for 3 weeks. For
Hepatocytes transplantation mice were injected with
Retrosine to arrest the cell division in liver and for he-
patocytes transplantation, the cultured hepatocytes
were injected from the lower pole of spleen and CCl4
injection was injected (i.p) to stimulate the proliferation
of hepatocytes.
Results: The cell line derived from DDC induced liver
injury model was named PMH08 (Perpetual Mouse He-
patocytes) heaving polygonal shape, granular cytoplasm
and round nucleus.The cell line established by this
novel approach have all morphological and functional
characteristics of hepatocytes up to 300 continuous pas-
sages and the mice transplanted with PMH08 cell line
have higher survival rate then that of control group
(p < 0.05)
Conclusion: The hepatocytes cell line derived from
DDC induced liver injury would be the novel approach
for hepatocytes transplantation research .
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APHPB-0274
THERAPEUTIC STRATEGY BASED ON
RESECTION FOR HEPATOCELLULAR
CARCINOMA WITH VP3 AND 4 IN A
CURATIVE INTENT
K. Okuda, K. Takagi, Y. Goto, T. Shirahama,
Y. Nomura, Y. Maruyama, R. Kawahara, H. Sakai
and M. Yasunaga
Department of Surgery, Kurume University School of
Medicine, Kurume, Japan
Objectives: Some authors, especially in Asian countries,
have aggressively resected locally advanced hepatocellu-
lar carcinoma (HCC) with major portal vein tumor
thrombus (Vp3 and 4). However, the outcome is still
unsatisfactory, and there are controversies in selection
of therapeutic modalities and strategy. This paper
reviews our experience to resect HCC with Vp3 and 4,
and propose the therapeutic strategy in a curative
intent.
Methods: 35 HCC patients with VP 3 and 4 were
divided into two cohorts: 10 cases, who were initially
unresectable, underwent resection following tumor
reduction by successful IVR treatments (downstaged
resection; DSR) and 25 cases, who were initially resect-
able, underwent resection without pretreatment
(n = 23) or resection after unsuccessful IVR treatment
(n = 2) (non-DSR).
Results: An average tumor size was 69 mm in DSR
group and 60 mm in non-DSR. Five cases in DSR and
8 cases in the non-DSR had a VP4 tumor thrombus.
The 1-, 3- and 5- year survival rates were 89%, 65%,
65% in DSR and 56%, 37%, 15% in non-DSR, retro-
spectively (p = 0.0151). A multiple logistic regression
analysis revealed that downstaged resection was the
independent predictors of overall survival. In patholog-
ical investigation, the incidence of histological intrahe-
patic metastasis around a main tumor was significantly
low in DSR.
Conclusion: The results suggest successful induction
treatments to resection may reduce the malignant
aggressiveness of tumor, and downstaged resection
gives a chance of curative even in HCC with VP3 or 4.
In the era of effective chemotherapy, the goal of multi-
disciplinary treatment for locally advanced HCC
should be downstaged resection.
APHPB-0305
PARTIAL HEPATECTOMY VERSUS
TRANSCATHETER ARTERIAL
CHEMOEMBOLIZATION FOR
RESECTABLE MULTIPLE
HEPATOCELLULAR CARCINOMA
BEYOND MILAN CRITERIA: A RCT
L. Yin1, W. Zhou1, W. Lau2, E. Lai2 and M. Wu3
1Third Department of Hepatic Surgery, Eastern
Hepatobiliary Surgery Hospital, Shanghai, China;
2Department of Hepatic Surgery, Prince of Wales
Hospital, Hongkong, China; 3Department of Hepatic
Surgery, Eastern Hepatobiliary Surgery Hospital,
Shanghai, China
Objectives: The aim of this randomized comparative
trial (RCT) is to compare partial hepatectomy (PH)
with transcatheter arterial chemoembolization (TACE)
to treat patients with resectable multiple hepatocellular
carcinoma (RMHCC) outside of Milan Criteria.
Methods: This RCT was conducted on 173 patients
with RMHCC outside of Milan Criteria (a solitary
tumor up to 5 cm or multiple tumors up to 3 in num-
ber and up to 3 cm for each tumor) who were treated
in our centre from November 2008 to September 2010.
The patients were randomly assigned to the PH group
or the TACE group. The primary outcome measure
was overall survival (OS) from the date of treatment. A
multivariate Cox proportional hazards regression
analysis was performed to assess the prognostic risk
factors associated with OS.
Results: The 1-, 2-, and 3-year OS rates were 76.1%,
63.5%, and 51.5%, respectively, for the PH group com-
pared with 51.8%, 34.8%, and 18.1%, respectively, for
the TACE group (Log-rank test, v2 = 24.246,
p < 0.001). Multivariate Cox proportional hazards
regression analysis revealed the type of treatment (haz-
ard ratio, 0.434; 95% CI, 0.293–0.644, p < 0.001), num-
ber of tumor (hazard ratio, 1.758; 95% CI, 1.213–
2.548, p = 0.003) and gender (hazard ratio, 0.451; 95%
CI, 0.236–0.862, p = 0.016) were significant indepen-
dent risk factors associated with OS.
Conclusion: PH provided better OS for patients with
RMHCC outside of Milan Criteria than conventional
TACE. The number of tumor and gender were also
independent risk factors associated with OS for
RMHCC.
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APHPB-0327
IDENTIFICATION OF A METASTATIC
ALDH1A3-POSITIVE SUBTYPE OF
PANCREATIC DUCTAL
ADENOCARCINOMA DRIVEN BY A
KRASG12D/MEK-DEPENDENT MTOR
SIGNAL
B. Kong1, W. W. Wu1, T. Cheng1, M. Schlitter2,
P. Bruns1, I. Esposito2, J. Kleeff1 and C. Michalski1
1Department of Surgery, Technical University of
Munich, Munich, Germany; 2Institute of Pathology,
Technical University of Munich, Munich, Germany
Objectives: Human pancreatic ductal adenocarcinoma
(PDAC) is a highly metastatic tumor entity with fre-
quent activation of mTOR (mammalian target of rapa-
mycin) signaling. Frequent genetic alterations such as
acquisition of mutant KRASG12D, loss of PTEN (phos-
phatase and tensin homolog) or loss/mutation of p53 in
PDACs potentially contributes to mTOR activation
through the Tsc1-Tsc2 (tuberous sclerosis) complex.
However, the biological significance of different
mTOR-activating patterns remains undefined.
Methods: Using a set of compound mutant mouse
models, we characterized and dissected the oncogenic
effect of mTOR in pancreas. Prospectively collected
patient specimens and data were used to investigate the
clinical significance of mTOR signaling.
Results: Hyperactive mTOR signaling in the absence of
activated PI3K/Akt or Raf/Mek was not oncogenic but
rather induced degeneration of the exocrine pancreas,
dependent on p53; PI3K/Akt-dependent mTOR signal-
ing induced benign cystic tumors; but, Raf/Mek-depen-
dent mTOR signaling induced highly metastatic PDACs
characterized by tissue hypoxia and central necrosis.
Although mTOR signaling was activated dependent on
Raf/Mek, effective mTOR inhibition necessitated a dual
Mek- and PI3K-inhibition to overcome the immediate
signal feedback response. Microarray analysis identified
Aldh1a3 (aldehyde dehydrogenase family 1, subfamily
A3) as the specific biomarker for the signal activity
of Raf/Mek-dependent mTOR signaling that promotes
pancreatic carcinogenesis. Consistently, ALDH1A3
labeled a distinctive PDAC subtype in humans with a
significantly worse prognosis.
Conclusion: We thus provide genetic and functional
evidence that define Raf/Mek-dependent mTOR signal-
ing as a major therapeutic target for a metastatic
Aldh1a3-positive PDAC subtype.
APHPB-0333
ASSOCIATING LIVER PARTITION AND
PORTAL VEIN LIGATION FOR STAGED
HEPATECTOMY (ALPPS) IN PATIENTS
WITH SMALL-FOR-SIZE FUTURE
LIVER REMNANT AND CHRONIC
LIVER DISEASES
A. Chan, J. Dai, T. T. Cheung, S. H. Chok, T. T.
Wong, B. She and C. M. Lo
Department of Surgery, Queen Mary Hospital, Hong
Kong, Hong Kong, China
Objectives: To evaluate the ALPPS procedure for
obtaining adequate liver hypertrophy in patients requir-
ing major hepatectomy for liver cancer with small-for-
size future liver remnant (FLR), especially in patients
with chronic liver diseases.
Methods: Small-for-size was defined as [FLR volume
divided by estimated total liver volume (by Urata for-
mula) 9 100%] to be <30%. The first stage of ALPPS
entailed right portal vein ligation and in-situ liver split
along the Cantle’s line for extended right hepatectomy,
or right side of faciform ligament for right trisectionec-
tomy. Computed tomographic volumetry was performed
before the first stage of ALPPS, and one day before
completion hepatectomy.
Results: A total of 14 patients (hepatoblastoma: n = 1,
hepatocellular carcinoma: n = 13, and liver metastasis:
n = 1) received the ALPPS procedure. Among them, 11
(79%) patients were chronic hepatitis B carriers with
liver fibrosis. Preoperative FLR volumetry was
275.3 mL (112.6–410.0 mL). After a median waiting
time of 7 days, the FLR volume increased to 469.2 mL
(160.7–565.2 mL) ( p < 0.001), accounting for a median
volume gain of 47.5% (25.8–111.3%). The FLR:ESLV
% increased from 22.5% to 36.0% (p < 0.001). The left
portal flow increased substantially from 162 to 514 mL/
min (p = 0.046) without significant change in portal
pressure (from 10.0 to 16.5 mmHg, p = 0.06). Postoper-
ative recovery was uneventful except in two patients who
developed complications (intestinal obstruction, n = 1;
bleeding, n = 1) with the latter one died of liver failure.
The median follow up was 175 days with an estimated
overall survival of 92.9%.
Conclusion: The ALPPS procedure effectively achieves
rapid FLR hypertrophy, and enables a timely curative
resection in patients with, otherwise marginally resect-
able liver cancer.
Transplantation
APHPB-0350
DEFINING THE INFLUENCE OF
GENDER DISCORDANCE ON
SURVIVAL FOLLOWING LIVE DONOR
LIVER TRANSPLANTATION
J. T. Miura, A. H. Fathi, F. M. Johnston, S. Tsai,
K. K. Christians, K. K. Turaga and T. C. Gamblin
Surgery, Medical College of Wisconsin, Milwaukee, WI,
USA
Objectives: Donor-recipient gender discordance has
been suggested to be an independent predictor of poor
© 2015 The Authors
HPB © 2015 Americas Hepato-Pancreato-Biliary Association HPB 2015, 17 (Suppl. S2), 1–24
12 Oral Abstracts
outcomes following deceased donor liver transplantation
(DDLT). Whether a similar trend occurs with live donor
liver transplants (LDLT) remains ill defined. The present
study sought to evaluate the association between gender
mismatch and survival following LDLT.
Methods: Patients that underwent LDLT were identi-
fied from the Organ Procurement and Transplant Net-
work database (2000–2012), and categorized by the
following donor-recipient gender groups: Female (F)/F,
Male (M)/F, M/M, and F/M. Log rank test and multi-
variable Cox proportional hazards models were used to
assess graft survival (GS) and overall survival (OS) of
the study groups.
Results: A total of 3143 LDLT were identified: 731 F/
F, 794 M/F, 1015 M/M, and 603 F/M. Ten year GS
and OS were highest in the F/F group, at 62% and
54% respectively, as compared to M/F (53%, 48%),
M/M (55%/46%), and F/M (55%, 49%). Multivariate
analysis demonstrated that gender mismatch was not
associated with poorer GS (MM: Reference; MF: HR
1.13, p = 0.22; FF: HR 0.9, p = 0.34; FM: HR 1.09,
p = 0.42). Independent factors associated with poorer
GS included older recipient age (HR: 1.01, 95% CI:
1.00–1.02; p = 0.001), increasing donor age (HR: 1.01,
95%CI: 1.00–1.02; p = 0.004), and higher Model for
End-stage Liver Disease score (HR: 1.02, 95%CI: 1.00–
1.03; p = 0.018).
Conclusion: Donor-recipient gender discordance does
not impact both GS and OS following LDLT. Living
donor organ allocation in an era of supply limitation
should not be influenced by donor gender.
Malignant HPB Diseases
APHPB-0378
ONCOLOGICAL EFFICACY OF
RADIOFREQUENCY ABLATION AND
TRANSARTERIAL
CHEMOEMBOLIZATION FOR
TREATMENT OF RECURRENT
HEPATOCELLULAR CARCINOMA: A 10-
YEAR COMPARATIVE SURVIVAL
ANALYSIS
P. S. Koh, A. C. Chan, T. T. Cheung, K. S. Chok,
W. C. Dai, R. T. Poon and C. M. Lo
Department of Surgery, The University of Hong Kong,
Hong Kong, China
Objectives: Radiofrequency ablation (RFA) and tran-
sarterial chemoembolization (TACE) have been shown
to be effective for recurrent hepatocellular carcinoma
(HCC) after hepatectomy. However, there is limited
data comparing the oncologic efficacy of these two
treatment modalities. This study aims to assess if RFA
confers any oncological superiority over TACE in post-
hepatectomy recurrent HCC.
Methods: From 2002–2011, 823 patients received hepa-
tectomy for primary HCC and 495 (60.15%) patients
developed postoperative tumor recurrence. 102 patients
received either RFA or TACE as salvage treatment
when the tumors were not resectable nor transplanta-
ble. Clinicopathological data and survival outcomes
were reviewed. Survival analysis was conducted by
Kaplan-Meier methods and compared using log-rank
test.
Results: Patient demographics and the primary tumor
characteristics between the two treatment groups were
similar (p > 0.05). The TACE group had earlier time to
recurrence after primary treatment than the RFA
group (5.92 vs. 8.92 months, p = 0.004). Overall sur-
vival after initial hepatectomy (p = 0.282) and salvage
treatment for recurrence (p = 0.824) were similar. The
1- and 5- year overall survival after salvage treatment
for RFA were 77.2% and 24.1%, and the correspond-
ing survival rates for TACE were 79.3% and 25.7%
respectively. For patients with second recurrence after
salvage teatment, an interchangeable treatment strategy
of RFA and TACE conferred significantly better sur-
vival outcome than stand-alone treatment with RFA or
TACE (p = 0.018).
Conclusion: RFA and TACE are equally effective for
intrahepatic recurrence after hepatectomy when re-
resection or salvage transplantation is considered not
feasible.
APHPB-0379
THE SPLEEN FROM HYPERSPLENISM
DUE TO PORTAL HYPERTENSION
INDUCES GROWTH AND
PROLIFERATION IN HUMAN HCC
CELL LINES
Y. Ji1, J. U. N. Sun2, Z. Wang3, J. U. N. Li2, W. E. I.
Jiang3, K. Chen3, X. Liu3, J. U. N. Yang2 and Z. Li3
1Scientific Research Center, The Second
AffiliatedHospital College of Medicine Xi’an Jiaotong
University, Xi’an, China; 2National & Local Joint
Engineering Research Center of Biodiagnosis and
Biotherapy, The Second AffiliatedHospital College of
Medicine Xi’an Jiaotong University, Xi’an, China;
3General Surgery, The Second AffiliatedHospital College
of Medicine Xi’an Jiaotong University, Xi’an, China
Objectives: To explore effects of spleen from hypersple-
nism due to portal hypertension (PH) on growth and
proliferation in human hepatocellular carcinoma cell
lines and its molecular mechanisms.
Methods: Serum of before, 1 and 2 weeks postsplenec-
tomy from patients with hypersplenism due to PH were
collected and stored. Human HCC cell lines (HepG2?
SMMC-7721?MHCC97-H) were cultured and stimu-
lated with different concentrations of the serum for the
indicated time (24 h, 48 h and 72 h). Growth of cells
was examined by MTT. The clone formation efficiency
of cells was determined by plate clone formation exper-
iment. Expressions of characteristic markers of prolifer-
ation (PCNA and C-myc) were identified with
immunofluorescence, western-blot and quantitative real
time-PCR.
Results: HCC cell lines induced by serum showed a
morphological alteration. Cell growth was significantly
enhanced by serum of before splenectomy (p < 0.05),
but reduced by serum from patients 1w and 2w
postsplenectomy. Immunofluorescent expressions of
PCNA and C-myc were obviously increased by serum
of before splenectomy (p < 0.05), but decreased by
serum from patients 1w and 2w postsplenectomy.
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Meanwhile, compared with the control, before sple-
nectomy group evidently elicited mRNA and protein
expressions of PCNA and C-myc in HCC cell lines
(p < 0.05), but 1w and 2w postsplenectomy groups
lessened mRNA and protein expressions of PCNA
and C-myc.
Conclusion: The present study indicates that serum
from patients with hypersplenism due to PH could
induce growth and proliferation in human HCC cell
lines. These findings might provide an innovative way
to explore the relationship between the spleen and the
progression of HCC.
APHPB-0388
INCOMPLETE RADIOFREQUENCY
ABLATION-GENERATED HEAT SHOCK
RESPONSE PROVOKES COLORECTAL
CANCER LIVER METASTASES (CRLMS)
RECURRENCE BY INDUCING CANCER
CELL STEMNESS AND INVASION
Z. Zhang, W. Zhang, Y. Wu, H. Liang, B. Zhang and
X. Chen
Hepatic Surgery Center, Tongji Hospital, Wuhan, China
Objectives: Even now, radiofrequency ablation (RFA)
is accepted as a curative therapy for colorectal cancer
liver metastasis (CRLMs). Accumulating data have
shown that incomplete radiofrequency ablation (ICR)
associates with increase of tumor recurrence and more
aggressive malignant phenotype. We determined the
mechanisms of this progression, including effectively
predict biologic behaviors.
Methods: We established a mouse model highly mim-
icking the process of RFA treatment. Functional stud-
ies were performed in vitro and in vivo.
Results: Our xenograft model unveiled ICR increases
the risk in CRLMs recurrence. Here we focused on the
heat shock (HS)-induced CRC malignance. Sublethal
HS in CRC cell lines provoked cell growth, invasion,
and tumor initiation in vitro. Consistently, the xeno-
graft mouse model also confirmed the effects of HS in
promoting tumor growth. With Western blot analysis,
we found that Fra-1, which is a typical down-stream of
the transcription factor ERK1/2, was significantly
increased by heat shock stimuli compared with the
untreated CRC cells. Furthermore, we demonstrated
that silence of Fra-1 in HS treated cells could abolish
the effects of HS in promoting malignant phenotype.
Significantly, proliferation markers (Ki67, c-Myc, Cyc-
linD1, CDK2), stem cell markers (Sox-2, Sox-9, Oct3/4,
Lgr5) and invasion related MMP1 were up-regulated in
the HS treated cells and in xenograft model. Taken
together, this study established a novel mouse model to
study the effect of ICR in CRLM.
Conclusion: HS induces CRC proliferation and metas-
tasis by targeting Fra-1, which is a potential prognostic
marker and a promising therapeutic strategy for CRC
recurrence after RFA treatment.
Transplantation
APHPB-0410
SURVEY OF THE SELF-MANAGEMENT
AND SELF-EFFICACY STATUS IN
PATIENTS AFTER ORTHOTOPIC LIVER
TRANSPLANTATION
R. Tao1, Q. Y. Chen2, X. Q. Liu1, Y. Cheng3 and
Z. Q. Hu4
1Hepatobiliary-Pancreatic Surgery, Zhejiang Provincial
People’s Hospital, Hangzhou, China; 2Infectious
Diseases, Shanghai Public Health Clinical Center,
Shanghai, China; 3Medical Statistics, Biomedical
Research Center Novartis (China), Shanghai, China;
4General Surgery, Central Hospital of Minhang District,
Shanghai, China
Objectives: Despite their well-recognized significance in
improving the outcome across a variety of chronic ill-
nesses, little work has been done regarding the impact
of self-management and self-efficacy on the health out-
comes after adult organ transplantation. We attempted
to have an overall understanding of the status quo of
postoperative self-management behaviors and perceived
self-efficacy in a group of liver transplantation (LT)
recipients.
Methods: A ‘Self-management Questionnaire for LT
Recipients’ modified from the Chinese version of
‘Chronic Disease Self-management Program Question-
naire Code Book’ was used in the current survey. Data
were collected by self-administered questionnaires from
124 LT patients. Total scoring Indicator was calculated
and influential factors for self-management behavior
and perceived self-efficacy were identified.
Results: Self-management in LT recipients is mainly
composed of exercise, cognitive symptom management,
communication with physicians and lifestyle manage-
ment, and the overall status was not optimistic. The
major variables affecting the self-management of LT
recipients were marital status, educational level and
employment. The overall status of self-efficacy in LT
recipients was around the mid-level. Years post-trans-
plantation and self-assessment of overall health state
were identified as factors which had an impact on self-
efficacy.
Conclusion: The self-management behavior of LT
recipients needs to be improved. Our health care pro-
fessionals are obligated to understand the problems
and needs of LT recipients when we carry out self-man-
agement support and implement targeted interventions
to help them develop better coping skills and achieve
satisfactory life quality. The development of the multi-
level and multifaceted social support system will greatly
facilitate the self-management activity in LT patients.
© 2015 The Authors
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APHPB-0416
IMPACT OF THE RECONSTRUCTION
MATERIAL ON THE PATENCY OF
MIDDLE HEPATIC VEIN IN LIVING
DONOR LIVER TRANSPLANTATION
USING THE RIGHT LIVER
S. Lee, E. Kim, J. Lee, G. Na, T. Hong, D. Kim and
Y. You
Hepatobiliopancreas, Seoul St.Mary’s Hospital, Seoul,
Korea
Objectives: The patency of reconstructed middle hepa-
tic vein (MHV) in adult-to-adult living donor liver
transplantation (LDLT) affects the recovery of graft.
The aim of the study is to evaluate the patency rate of
reconstructed MHV according to the material.
Methods: From August 2003 to December 2012 at the
Seoul St. Mary’s Hospital, 429 patients underwent
LDLT with MHV reconstruction. At first comparison,
patients divided into 2 groups: biologic group (n = 252)
and synthetic group (178). We compared the patency
MHV among these groups by Computed Tomography
angiography at 7, 20, 90 days, and 1 year. At second,
patients were divided into six groups: MHV was recon-
structed by Greater Saphenous Vein (GSV) (n = 20);
recipient’s Portal Vein (PV) (n = 219); Cryopreserved
iliac artery (CIA) (n = 2); Cryopreserved iliac vein
(CIV) (n = 11); PTFE (n = 105); PETE (n = 72).
Results: At first comparison, postoperative 7 days bio-
logic group 61.9%, synthetic group 72.4% (p = 0.029),
and postoperative 1 year 42.95%, 24.1% (p = 0.001).
At second comparison, postoperative 7 days, MHV
patency rates were GSV 65.0%, PV 62.5%, CIA 50%,
CIV 63.6%, PTFE 75%, PETE 72% (p = 0.318). At
postoperative 20 days’ result was 60%, 57.1%, 50%,
54.5%, 69%, 55.6% (p = 0.444). At 90 days’ result was
40%, 48.8%, 50%, 27.3%, 47%, 34.1% (p = 0.294).
And at 1 year later, result was 30%, 45.2%, 50%,
27.3%, 27%, 26.4% (p = 0.008).
Conclusion: There was significant difference in MHV
patency rates of biologic and synthetic two group com-
parison. Therefore, synthetic graft could be considered
in living donor liver transplantation with MHV recon-
struction.
APHPB-0418
SAFETY OF PERIOPERATIVE ASPIRIN
IN HEPATOCELLULAR CARCINOMA
PATIENTS UNDERGOING
HEPATECTOMY
T. Wong, M. P. Chan, T. T. Cheung, K. S. Chok, A.
C. Y. Chan, W. C. Dai, S. C. Chan, R. T. Poon and
C. M. Lo
Surgery, The University of Hong Kong, Hong Kong,
Hong Kong China
Objectives: Aspirin is shown to reduce perioperative
mortality in non-cardiac surgery. Hepatectomy was
associated with significant risk of bleeding and it is a
common practice to stop aspirin for 7–10 days before
hepatectomy. The aim for this study was to investigate
whether it was safe to continue aspirin in perioperative
period.
Methods: This was a retrospective study from Queen
Mary Hospital, Hong Kong. Outcomes of all patients
who were on aspirin and had undergone hepatectomy
were analyzed.
Results: From 2000 to 2013, 53 aspirin-users underwent
hepatectomy in our centre. Aspirin was continued in 27
patients and it was discontinued for at least 5 days
before hepatectomy in the remaining 26 patients. There
was no difference in patients’ demographics including
age (67 vs. 71, p = 0.099), sex (% male: 88.5 vs. 77.8
p = 0.503), hepatitis B status (65.4% vs. 63%,
p = 0.980), comorbidity (96.2 vs. 96.3%, p = 1.000) and
Child stage (% Child’s A: 100 vs. 96.2, p = 1.000).
Platelet coun (186 vs. 180 9 109/L, p = 0.812), INR
(1.1 vs. 1.0, p = 0.591) were also comparable.
Operative procedure (% major hepatectomy: 37.0 vs.
42.3%, p = 0.689) and blood loss (0.89 vs. 0.57L,
p = 0.196) were similar. There was no hospital mortal-
ity and complication rate was the same (30.8 vs.
25.9%, p = 0.696). In those who continued aspirin, one
developed peptic ulcer bleeding and 1 had intra-abdom-
inal bleeding required laparotomy. Three patients in
whom aspirin was stopped had perioperative cardiovas-
cular events but risk was the same in those who contin-
ued aspirin (11.5 vs. 3.8, p = 0.603).
Conclusion: Perioperative use of aspirin was safe with-
out increased risk of bleeding and complication.
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APHPB-0428
EFFICACY OF HEPATITIS B VIRUS
PROPHYLAXIS WITH COMBINATION
THERAPY USING HEPATITIS B
IMMUNOGLOBULIN AND TENOFOVIR
IN LIVER TRANSPLANT RECIPIENTS
Y. Yoon, H. Shin, S. O. N. G. Gi-Won, J. U. N. G.
Dong-Hwan and L. E. E. Sung-Gyu
LTS, asan medical center, Seoul, Korea
Objectives: Background: Prevention of hepatitis B virus
(HBV) recurrence is essential after liver transplantation
(LT) in HBV-associated patients. This study intended
to evaluate the efficacy of combination therapy using
Hepatitis B immunoglobulin (HBIG) and tenofovir in
LT recipients, especially focused on high-risk patients
with high viral load and high-risk of hepatocellular car-
cinoma (HCC) recurrence.
Methods: A prospective study was performed with 210
HBV-associated adult patients who underwent LT
operation during June 2012 and December 2013 and
followed up until April 2014.
Results: Our precedent study revealed a 5-year HBV
recurrence rate of 7.3% on high-dose HBIG monother-
apy. Combination therapy of HBIG and entecavir
resulted in nearly no recurrence, but a considerable
proportion of patients showed HBV recurrence espe-
cially in recipients without HBIG/antiviral resistance
and HCC recurrence. In this study with 42% of HCC
patients, there was no occurrence of HBV recurrence
until now except one case, in whom HBsAg became
positive and HBV DNA turned to be detectable
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temporarily at dissemination of HCC recurrence but
HBV DNA became negative after HCC treatment.
Other 5 patients with HCC recurrence showed unde-
tectable DNA during follow-up.
Conclusion: Based on the mid-term results of this
study, combination therapy of HBIG and entecavir
appears to be effective to prevent or suppress HBV
recurrence even in high-risk patients with high viral
load, pre-existing antiviral resistance and high-risk of
HCC recurrence, thus we suggest this prophylaxis pro-
tocol to apply LT recipients with such high risk.
APHPB-0429
DIAGNOSIS AND TREATMENT OF
LATE POSTTRANSPLANT
HEPATOCELLULAR CARCINOMA
RECURRENCE AFTER 5 YEARS
Y. Yoon, H. Shin, H. A. Tae-Yong, S. O. N. G.
Gi-Won, J. U. N. G. Dong-Hwan and L. E. E. Sung-Gyu
LTS, asan medical center, Seoul, Korea
Objectives: Background: Most hepatocellular carci-
noma (HCC) recurrences following liver transplanta-
tion (LT) occur within first 3 years, but it happens
sporadically after 5 years. This study intends to review
the clinical features of late HCC recurrence and to
establish its long-term screening protocol.
Methods: The study population were 334 patients with
HCC who underwent primary LT with follow-up per-
iod of >5 years.
Results: Overall 10-year patient survival rate was
67.5%, with 4.8% perioperative mortality. HCC
recurred in 68 (21.4%) of 318 surviving patients. HCC
recurrence rate was 20.7% at 5 years and 23.2% at
10 years. Annual recurrence rate was 11.4%, 6.6%,
and 2.0% during the first, second, and third year,
respectively. In patients within Milan criteria, annual
incidence of HCC recurrence was highest during first
3 years, while thereafter 6 cases of sporadic recurrence
occurred after 5 years; in patients beyond Milan crite-
ria, no late recurrence was found after 5 years.
Increases in alpha-fetoprotein (AFP) were determined
to be an initial indication to perform further imaging
studies to diagnose recurrence in 4. There was a close
correlation between pretransplant AFP level and AFP
rise after HCC recurrence. Initial recurrence site was
extrahepatic in 5 and intrahepatic in 1. Their median
survival period after recurrence was 18 months.
Conclusion: We suggest that patients within Milan
criteria are indicated for regular follow-up over 10 years,
primarily with tumor marker tests.
Malignant HPB Diseases
APHPB-0433
RISK FACTORS OF INTRAHEPATIC
CHOLANGIOCARCINOMNA REVISITED
W. Kwon, H. S. Lee, J. Y. Park, S. M. Youn, J. S.
Heo, S. H. Choi and D. W. Choi
Surgery, Samsung Medical Center Sungkyunkwan
University School of Medicine, Seoul, Korea
Objectives: Relatively little is known about the prog-
nostic factors of Intrahepatic cholangiocarcinoma
(ICC), the second most common liver malignancy. The
aim was to investigate the prognostic factors associated
with the survival and recurrence after curative resec-
tion.
Methods: 233 patients were operated with curative
intent between 1995 and 2012 at Samsung Medical
Center. Their medical records were retrospectively stud-
ied and analyzed to identify prognostic factors.
Results: The mean age was 59.9 years and male was
predominant. 52.4% received hemihepatectomy. R0
resection was achieved in 91.4%. Lymph node (LN)
dissection was performed in 113 patients. Mass forming
was the most common type, and multiple tumors were
found in 18.5%. LN metastasis was present in 54.2%.
The 3 and 5-year survival rates were 49.9% and
41.8%. The 3 and 5-year disease-free survival rates
were 30.7% and 26.8%. After multivariate analysis,
history of biliary stones (p = 0.026), elevated CEA
(p = 0.007), R2 resection (p < 0.001), intraductal
growth type (p = 0.032), size >5 cm (p = 0.026), and
LN metastasis (p < 0.001) were the independent prog-
nostic factors. Elevated CEA (p = 0.017), R2 resection
(p = 0.001), intraductal growth type (p = 0.010), size
>5 cm (p < 0.001), LN metastasis (p < 0.001), and peri-
neural invasion (p = 0.021) were found to be associated
with recurrence.
Conclusion: Widely accepted prognostic factors based
on western studies are tumor multiplicity, vascular
invasion, and LN metastasis. Of these three well-recog-
nized factors, LN metastasis was the only common fac-
tor in this study. Further, size was found to be a
prognostic factor unlike the western results. This study
draws attention to the need for reinvestigation of the
ICC prognostic factor.
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APHPB-0437
ERAS USING EARLY ENTERAL
NUTRITION PREVENTS SYSTEMIC
INFLAMMATORY RESPONSE
SYNDROME AND INFECTION AFTER
LIVING DONOR LIVER
TRANSPLANTATION
T. Onoe1, Y. Tanaka2, K. Ishiyama2, K. Ide2, M.
Ohira2, H. Tahara2, T. Abe2, H. Tashiro2 and H.
Ohdan2
1Institute for Clinical Research, National Hospital
Organization Kure Medical Center/Chugoku Cancer
Center, Kure, Japan; 2Department of Gastroenterological
and Transplant Surgery, Institute of Biomedical and
Health Sciences Hiroshima University, Hiroshima, Japan
Objectives: Liver transplantation is one of the most
invasive procedures in surgery and patients become
immunocompromised by immunosuppressant after sur-
gery. Emphasis has more recently been placed on the
enteral nutrition to hasten recovery as well as to modu-
late immune-status. In this study, we investigated the
impact of early enteral nutrition in living donor liver
transplantation (LDLT).
Methods: Between 2007 and 2012, LDLT were per-
formed in 109 patients. The patients were divided to
two groups, patients with or without an early enteral
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nutrition using glutamine-fiber-oligosaccharide mixture
(GFO) and whey peptide-based enteral formula diet
within 60 h after LDLT (EEN group and non-EEN
group, respectively) and were evaluated retrospectively.
Results: A multivariate analysis of factors (recipient,
donor, graft and surgical factors including EEN)
revealed that low graft-versus-recipient weight ratio
(GRWR) and non-EEN were significant risk factors for
the incidence of systemic inflammatory response syn-
drome (SIRS) on POD 10, infection and sepsis within
1 month after surgery. We next compared EEN and
non-EEN groups by statistical matching technique
using propensity score to estimate the impact of EEN
on infection. The characteristics of patients including
GRWR did not differ between the two groups. Analy-
sis revealed that incidences of SIRS, infection and sep-
sis in non-EEN group showed higher than those in
EEN group. Furthermore, the CRP value was signifi-
cantly lower in the EEF group than in the non-EEF
group during first week after LDLT.
Conclusion: Early enteral nutrition with GFO and
whey peptide-based enteral formula diet prevents post-
transplant systemic inflammatory response, infection
and bacteremia.
Benign HPB Diseases
APHPB-0459
INTRAOPERATIVE COELIAC PLEXUS
NEUROLYSIS COMBINED WITH FREYS
PROCEDURE FOR EFFECTIVE PAIN
RELIEF IN PATIENTS WITH CHRONIC
CALCIFIC PANCREATITIS-A
PROSPECTIVE RANDOMIZED
DOUBLE-BLIND TRIAL
B. Sathyamoorthy, R. Vellaichamy, S.
Sankareshwaran, A. Anbalagan, P. Raju, B.
Duraisamy, C. ServarayanMurugesan and K.
Devygounder
Institute of Surgical Gastroenterology, Madras Medical
College RajivGandhi Government General Hospital,
Chennai, India
Objectives: Even with freys procedure the rate of reccu-
rence of pain & analgesic drug usage is more expecialy
with alchoholic chronic pancreatitis and those with
small duct disease.
Methods: In a randomized double-blind study the
efficacy of intra operative neurolytic coeliac plexus
block (NCPB) was combined with freys procedure in
the treatment of pain from chronic calcific pancreati-
tis & improvement in QOL. Patients admitted with
CCP in our institution between march 2013 to july
2014 were randamised.Only 66 patients with intracta-
ble pain are included in the study .66 patients were
divided into two groups: 33 patients underwent
NCPB & Freys procedure (group 1) and 33 were
treated with only Freys procedure (group 2). Mean
follow up time was 11 months.Immediate and short -
term pain relief (calculated by VA Score), mean anal-
gesic consumption, mortality and morbidity & QOL
were evaluated at follow-up. Statistical analysis was
performed with the unpaired t test, and chi square
test.
Results: Patients In Group 1 reported significant pain
relief compared with those in group 2 (p < 0.05). Mean
analgesic consumption was lower in group 1. There
were no deaths. Complications related to NCPB were
transient diarrhoea and hypotension which was man-
aged conservatively.QOL improved significantly due to
improved pain score.
Conclusion: Freys procedure when combined with
NCPB was associated with effective both short & inter-
mediate term pain relief & reduction in analgesic drug
administration, representing an effective tool in the
treatment of pain & improving QOL in patients with
CCP. But long-term results need to be followed-up.
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APHPB-0460
HOW TO RESTORE PORTAL FLOW
USING PERICHOLEDOCHAL VARIX IN
ADULT LIVING DONOR LIVER
TRANSPLANTATION FOR COMPLETE
PORTAL VEIN THROMBOSIS
PATIENTS
D. B. Moon, S. G. Lee, G. C. Park, K. H. Kim, T. Y.
Ha, G. W. Song, D. H. Jung, Y. I. Yun, W. J. Kim
and M. H. Shin
Hepatobiliary Surgery and Liver Transplantation, Asan
Medical Center University of Ulsan College of Medicine,
Seoul, Korea
Objectives: If most of the splanchnic venous blood
drains into large pericholedochal varix through the
peripancreatic collateral, large pericholedochal varix
can be used for portal inflow to the transplanted liver
and also relieve recipient’s portal hypertension. To
date, however, there has been no successful report
using pericholedochal varix in liver transplantation.
Methods: At our institution, 4 patients among 2166
adult LDLT recipients (Jan. 2006 – May. 2013) had
totally obstructed portal vein and co-existing large
pericholedochal varix without large amount of ascites.
Pericholedochal varix was the only available portal
inflow securing successful LDLT in 2 patients, and was
also alternative inflow for superior mesenteric vein in
another 2 patients. The surgical strategies are follow-
ings: (a) dissection of hepatic hilum to isolate left hepa-
tic artery using for arterial reconstruction of implanted
right lobe graft, (b) en-mass clamping of the undis-
sected remaining hilum if we can leave adequate length
of stump from the clamping site, and then hilum is
divided, (c) delay the donor hepatectomy until the fea-
sibility of the recipient operation is confirmed.
Results: From divided hepatic hilum under clamp,
more than 1 cm caliber pericholedochal varix was
obtained from single, or more than two varix through
venoplasty. Donor portal vein was fenced in funnel
shape at the bench for safe and easy anastomosis with
plastied cholechal varix. Implantation and postopera-
tive recovery were uneventful. Currently, all the recipi-
ents are doing well without portal hypertension related
complications.
Conclusion: Enlarged pericholedochal varix can be suc-
cessfully used for portal inflow of adult LDLT in
patients with totally obliterated portal vein.
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APHPB-0466
RECURRENT COMMON BILE DUCT
STONES AS A LATE COMPLICATION
OF ENDOSCOPIC SPHINCTEROTOMY
G. R. Guerra, T. Nzenza, T. Yong and T. McQuillan
Department of Surgery, Northern Health, Melbourne,
Vic., Australia
Objectives: Endoscopic retrograde cholangiopancrea-
tography (ERCP) + endoscopic sphincterotomy (ES)
has become well established as a modality for the man-
agement of bile duct stones. Our study aims to deter-
mine the rate of recurrent primary common bile duct
(CBD) stones post ES.
Methods: A retrospective analysis of patients undergo-
ing ERCP + ES was undertaken on a prospectively
maintained database from 1998 to 2012 at the North-
ern Hospital, Melbourne. The recurrence of primary
bile duct stones was defined as the detection of stones
no sooner than 6 months after complete clearance of
the CBD. Prior cholecystectomy was a requirement for
inclusion.
Results: 1148 patients underwent ERCP, of which 571
had an ES. 43 patients required a repeat ERCP for
recurrence of primary CBD stones, a complication rate
of 7.5%. The range for recurrence was from 6 months
– 10 years with a mean of 4.5 years. 32% of patients
required multiple procedures including repeat ES. Fac-
tors associated with recurrence of stones included a
dilated common bile duct >12 mm, narrowing of the
endoscopic sphincterotomy to 2–5 mm and the pres-
ence of the ampulla within or on the edge of a divertic-
ulum.
Conclusion: The results demonstrate that ERCP + ES
has an inherent long term complication rate of recur-
rent primary duct stone formation. While this can be
managed with repeat ERCP  ES, given the advent of
laparoscopic transcystic bile duct exploration, the use
of ERCP + ES in younger patients needs to be exam-
ined against laparoscopic methods in the setting of a
trial.
Transplantation
APHPB-0488
STANDARD FORMULAE IN
PREDICTING LIVER VOLUME USING A
SINGLE CENTRE SOUTH EAST ASIAN
SERIES OF ADULT LIVING DONORS
S. A. Lui, S. Lee, G. K. Bonney, A. Kow, S. G. Iyer,
S. Chang and K. K. Madhavan
Hepatobiliary Surgery, NUH, Singapore, Singapore
Objectives: In recent years, numerous formulae have
been derived to predict liver volumes. To date, no such
study has been carried out in a South East Asian popu-
lation. Our aims were to study the accuracy of seven
internationally recognized formulae and derive a for-
mula for calculating the weight of a liver graft using
CT derived volumes.
Methods: A prospectively held database of adult living
donor liver transplants between July 1996 and July 2014
was interrogated. The accuracy of seven internationally
well recognized formulae was compared to the CT gener-
ated volume. Finally, a correlation formula between CT
volume and actual graft weight is described.
Results: Seventy out of eighty seven living adult donors
had complete data allowing downstream analysis. None
of the seven formulae were accurate at predicting vol-
ume and were similar in accuracy. However, the for-
mula by FuGui et al (China) showed the closest
correlation with CT volumetry (r2 = 0.537). Finally, we
derived a formula to calculate weight of the graft based
on predicted CT volumetry (Weight (g) = 0.87 9 Vol
(cm3) + 70.02) with good accuracy (r2 = 0.9).
Conclusion: We describe here the most reliable formula
for predicting liver volume in a South East Asian popu-
lation. Also, with good accuracy we propose a formula
for calculating the weight of a liver graft based on CT
volumetry.
Malignant HPB Diseases
APHPB-0497
PREOPERATIVE PLATELET-
LYMPHOCYTE RATIO AS A
PREDICTOR OF MALIGNANCY IN
CHRONIC CALCIFIC PANCREATITIS
WITH HEAD MASS: PLATELET-
LYMPHOCYTE RATIO VERSUS CA 19.9
U. Muthuswamy, S. Jeswanth, P. Senthilkumar, P.
Anbalagan, R. Kamalakannan, B. Kesavan, R. Ravi,
P. Ravichandran and G. Manoharan
Department of Surgical Gastroenterology, Stanley
Medical College, Chennai, India
Objectives: Differentiating inflammatory from malig-
nant head mass in the background of chronic calcific
pancreatitis (CCP) is difficult, but there is no investiga-
tion which can reliably solve this dilemma. An accurate
diagnosis is crucial as the treatment is different for the
two cases and a failure to identify malignancy before
surgery can be disastrous. We aimed to assess the
accuracy of platelet-lymphocyte ratio (PLR) and to
compare it with CA19.9 in determining the nature of
PHM.
Methods: Eighty three patients who presented with
CCP and PHM between 2005 and 2011, were included
in the study. Patients identified to have malignancy
underwent Pancreaticoduodenectomy, while those
deemed to have a benign lesion underwent Frey’s pro-
cedure.Clinical features of both the groups were com-
pared. CA 19-9 and PLR individually and in
combination were compared in both groups. Receiver
operating characteristic curves (ROC) were used to
analyse the predictive values of CA19-9 and PLR indi-
vidually and together.
Results: Histologically, 66.3% had an inflammatory
head mass and 33.7% had a malignant head mass.Sig-
nificant clinical features which predicted a malignancy
included the presence of a head mass in CCP of tro-
pics, older age, jaundice, sudden worsening abdominal
pain, gastric outlet obstruction and significant weight
loss. Sensitivity and Specificity of CA 19-9 and PLR in
diagnosing malignancy were similar (65.7 vs. 63.6% &
96.5 vs. 95.8% respectively), on combining CA 19-9 &
PLR there was an improvement in sensitivity (84.8%).
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Conclusion: PLR is atleast as good as CA 19-9 as a
diagnostic marker to differentiate between malignant
and inflammatory head mass in CCP. When used
together, PLR improves the predictive value of serum
CA19-9.
APHPB-0517
POTENT PROGNOSTIC IMPACT OF
THE LYMPH NODE RATIO ON
SURVIVAL AFTER RESECTION FOR
EXTRAHEPATIC
CHOLANGIOCARCINOMA
J. Suh1, S. Jo1, S. Song1 and W. Lee2
1Surgery, Dankook University College of Medicine,
Cheonan, Korea; 2Pathology, Dankook University
College of Medicine, Cheonan, Korea
Objectives: Recent studies have revealed that the lymph
node ratio (LNR), the ratio of the number of meta-
static lymph nodes to the total number of lymph nodes
removed, is useful for predicting survival outcome in
several cancers. This study was performed to investi-
gate prognostic impact of the LNR on survival in
patients undergoing resection for extrahepatic cholan-
giocarcinoma (EHCC).
Methods: We retrospectively analyzed a total of 60
consecutive patients who underwent curative intent
resection for EHCC. Multiple prognostic factors were
examined with focus on LNR, which was divided into
three groups as follows: 0 in 31 patients, between 0 and
0.2 in 24 patients, and greater than 0.2 in 5 patients.
Results: The average number of removed lymph nodes
was 15.5 (1–48). The 5-year survival rates for patients
with LNRs of 0, 0–0.2, and ?0.2 were 51.1%, 15.1%,
and 0%, respectively (p < 0.001). Absence of jaundice
at diagnosis (p = 0.008), tumor cell differentiation
(p = 0.001), papillary gross appearance (p = 0.040),
lymphovascular invasion (p = 0.009), TNM stage
(p = 0.002), lymph node metastasis (p < 0.001), LNR
(p < 0.001), and surgical margin (p = 0.002) were pro-
ven significant prognostic factors by univariate analysis.
Multivariate analysis demonstrated that LNR
(OR = 7.82), age, absence of jaundice at diagnosis, cell
differentiation, and surgical margin were independent
prognostic factors.
Conclusion: LNR was a potent prognostic predictor of
survival in surgical patients with EHCC. Therefore,
LNR should be taken into consideration in determining
patient-tailored treatment.
Benign HPB Diseases
APHPB-0537
CLINICAL IMPLICATION OF TUMOR
MARKER FOR INTRADUCTAL
PAPILLARY MUCINOUS NEOPLASM
J. Kim
General Surgery, Seoul National University Hospital,
Seoul, Korea
Objectives: Several malignancy predictors are suggested
for intraductal papillary mucinous neoplasm (IPMN).
However, little is known about prognostic significance
of serum carbohydrate antigen (CA) 19-9 and carcino-
embryonic antigen (CEA).
Methods: We analyzed 375 surgical biopsy proven
IPMN patients in order to explore malignancy predict-
ing power of tumor markers. Cut-off value of tumor
markers for malignancy prediction of IPMN was statis-
tically drawn.
Results: Of the patients, 117 (31.1%) patients had
malignant pathology (high grade dysplasia and invasive
IPMN). Serum CEA was elevated (>5 lg/L) in 4.4%,
and serum CA19-9 was elevated (>37 U/mL) in 16.1%
of the patients. Elevated serum CEA was not signifi-
cantly different according to malignancy or ductal type.
Serum CA19-9 was significantly elevated in malignant
IPMN (34.2% vs. 7.6%, p < 0.001) and main duct type
IPMN (40.0% vs. 14.3%, p = 0.001). Multivariate
analysis revealed main pancreatic duct >5 mm
(p = 0.047), mural nodule (p < 0.001), and elevated
serum CA19-9 (p < 0.001) as independent malignancy
predictors. Receiver – operator characteristic curve
analysis revealed cut-off value of CEA 4.5 lg/L and
CA19-9 57.6 lg/L for highest malignancy prediction
power. Sensitivity, specificity, accuracy, positive predic-
tive value, and negative predictive value of malignancy
at the level of CA19-9 57.6 lg/L was 25.6%, 96.0%,
73.4%, 75.0% and 73.2%, respectively.
Conclusion: Serum CA19-9 level was significantly
higher in malignant IPMN and main duct type IPMN.
Statistically drawn serum CA19-9 cut-off value for
malignancy prediction was 57.6 lg/L. Serum CA19-9
level can be used as a malignancy predictor of IPMN.
APHPB-0543
INCIDENCE OF ENDOCRINE
FUNCTION IMPAIRMENT AFTER
DISTAL PANCREATECTOMY AND ITS
RELATED FACTORS
J. Kang, J. Jang, M. Kang and S. Kim
Department of Surgery, Seoul National University
Hospital, Seoul, Korea
Objectives: Incidence and risk factors of post-pancrea-
tectomy glucose intolerance are not well investigated
before. This study was aimed to figure out clinicopath-
ologic factors associated with development of glucose
intolerance or overt diabetes mellitus (DM) after distal
pancreatectomy (DP), and to investigate correlation
between resected pancreas volume and endocrine func-
tion impairment.
Methods: Excluding those with preoperative DM, a
total of 101 patients was enrolled in this prospective
cohort study, who underwent DP with minimum 1 year
postoperatively follow up. Oral glucose tolerance test,
HbA1c and pancreatic volumetry were consecutively
checked at preoperative, immediate postoperative per-
iod and postoperative 1 year.
Results: Among the study subjects, 20.8% had pancre-
atic ductal adenocarcinoma. After 1 year of DP, 51
patients (50.5%) had impaired fasting glucose (n = 26)
or DM (n = 25). Univariate analysis revealed female
sex (58.5% vs. 36.1%, p = 0.031), higher body mass
index (BMI) (24.1 vs. 22.5, p = 0.010) and larger
resected volume (36.5% vs. 28.0%, p = 0.026) were risk
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factors for postoperative endocrine function impair-
ment. Multivariate analysis revealed female sex (OR
5.818, p = 0.003), higher BMI (OR 10.556, p = 0.006),
and resected pancreatic volume (OR 3.192, p = 0.035)
were independent risk factors. Threshold of maximum
diagnostic value for BMI was 20 and resected volume
was 25% in ROC curve analysis.
Conclusion: Among patients without preoperative DM,
impaired glucose tolerance or overt DM develop in
50.5% of the patients after DP. Female sex, higher
BMI and resection of the pancreatic volume over 25%
are risk factors of endocrine function impairment,
therefore preoperative explanation and careful periop-
erative glucose monitoring is needed in these patients.
Malignant HPB Diseases
APHPB-0552
THE POTASSIUM CHANNEL BETA-
SUBUNIT, KCNE3, IS A NOVEL
PROGNOSTIC MARKER FOR
HEPATOCELLULAR CARCINOMA
E. Cho1, S. Kim1, E. Park2, K. Lee2, H. Shin2,
S. Park3 and C. Han4
1Surgery, Korea Cancer Center Hospital, Seoul, Korea;
2Division of Radiation Cancer Research, Korea Institute
of Radiological and Medical Sciences, Seoul, Korea;
3Pathology, Korea Cancer Center Hospital, Seoul,
Korea; 4Internal Medicine, Korea Cancer Center
Hospital, Seoul, Korea
Objectives: KCNE3, the regulatory b-subunit of the
voltage-gated potassium channel, controls cellular excit-
ability via potassium flux, and its overexpression
induces pore opening. In the present study, we identi-
fied KCNE3 as a novel prognostic marker for hepato-
cellular carcinoma (HCC), particularly in patients with
large tumors.
Methods: One-hundred and sixteen patients who had
HCC were enrolled in this study. We investigated the
expression of KCNE3 gene. The patients were divided
into two groups according to the KCNE3 gene expres-
sion levels in the tumor tissue. Clinical data were com-
pared between the two groups.
Results: Quantitative analysis with real-time RT-PCR
revealed high KCNE3 expression in HCC but not adja-
cent liver tissues (mean transcript levels, 5.16- and 1.41-
fold, respectively, p = 0.004), compared to those of tis-
sues with normal liver characteristics. The overall and
recurrence-free survival rates of HCC patients with lar-
ger (>5 cm) but not smaller (≤5 cm) tumors were signif-
icantly differentiated on the basis of KCNE3
expression. KCNE3 overexpression over a broad range
was associated with survival in the patient subgroup
with larger tumors, whereby HCC patients expressing
higher levels of KCNE3 exhibited poorer overall and
recurrence-free 5-year survival rates than those with
lower levels (30.0% vs. 59.4% and 15.0% vs. 53.1%,
respectively, based on 5.0-fold overexpression cutoff).
Conclusion: KCNE3 overexpression provides a novel
poor prognostic marker in HCC patients, particularly
those with large tumors. We propose that KCNE3-medi-
ated alterations in voltage-gated potassium channel
activity affect the progression and clinical outcomes of
HCC in association with tumor size.
APHPB-0558
LOCAL CONTROL BY
RADIOFREQUENCY THERMAL
ABLATION INCREASED OVERALL
SURVIVAL IN PATIENTS WITH
REFRACTORY LIVER METASTASIS OF
COLORECTAL CANCER
P. C. Yang1, B. R. Lin2, Y. C. Chen3, H. S. Lai2,
K. W. Huang2 and J. T. Liang2
1Surgery department, National Taiwan University
Hospital Hsinchu Branch, Hsinchu City, Taiwan;
2Surgery department, National Taiwan University
Hospital, Taipei City, Taiwan; 3Medical imaging
department, National Taiwan University Hospital, Taipei
City, Taiwan
Objectives: Radiofrequency thermal ablation has been
widely used for local solitary liver tumor control. How-
ever, a definitive role for radiofrequency thermal abla-
tion has not been established in patients with colorectal
liver metastasis refractory to chemotherapy. This study
aimed to evaluate the outcomes of radiofrequency ther-
mal ablation and to identify potential prognostic fac-
tors in patients with refractory colorectal liver
metastases.
Methods: We retrospectively enrolled 70 consecutive
patients with histologically proven adenocarcinoma of
the colon and rectum and synchronous liver metastasis,
who were referred to the National Taiwan University
Hospital between January 2007 and December 2009.
Data on age, gender, carcinoembryonic antigen level,
primary tumor location, postoperative adjuvant chemo-
therapy regimen, and size and number of metastatic
liver nodules were recorded. Cox regression analysis
was used to determine prognostic significance.
Results: Radiofrequency thermal ablation plus chemo-
therapy was associated with a better median overall
survival than chemotherapy alone (29 vs. 12 months;
p = 0.002). Patients with ≤5 and >5 liver metastatic
tumors had median survival durations of 28 and
17 months, respectively (p = 0.018. The dominant liver
tumor size (<5 vs. ≥5 cm) was significantly associated
with median survival (30 vs. 17 months; p = 0.038), as
was the carcinoembryonic antigen level (≤200 vs.
>200 ng/mL; 35 vs. 16 months; p = 0.029). In a multi-
variate analysis, only radiofrequency thermal ablation
treatment and the number of liver tumors were signifi-
cant prognostic factors for survival.
Conclusion: For patients with refractory synchronous
colorectal liver metastases, radiofrequency thermal
ablation was a safe and effective adjunct treatment to
chemotherapy.
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APHPB-0572
KIAA1199 PROMOTES STEMNESS
THROUGH ACTIVATING CANONICAL
WNT SIGNALING AS AN ESSENTIAL
TRANSCRIPTION FACTOR IN
PANCREATIC CANCER STEM CELLS
C. Y. Jang and S. Y. Song
Brain Korea 21 PLUS Project for Medical Science
Division of Gastroenterology Department of Internal
Medicine Institute of Gastroenterology, Severance
Hospital Yonsei University, Seoul, Korea
Objectives: Cancer stem cells (CSCs), raised as a poten-
tial target for cancer therapy, have been not clearly
characterized. Since we found that KIAA1199 was up-
regulated in pancreatic CSCs, here, we have examined
the function of KIAA1199 in pancreatic CSCs
Methods: Using adherent and sphere cells that
obtained from sphere cultivation, we validated
KIAA1199 mRNAs by qRT-PCR. Stably KIAA1199
over-expressed cell line (K10) was established. Using
K10 cells and siRNA that specific for KIAA1199, we
performed sphere formation and colony formation
assay in cancer cells. To elucidate tumorigenecity, we
executed xenograft in vivo and ChIP assay was per-
formed to check transcriptional activity.
Results: KIAA1199, over-expressed in sphere cells but
not in adherent cells of several pancreatic cancer cell
lines, showed positive regulation of self-renewal and
tumorigenesis in vitro and in vivo. Knock down of
KIAA1199 caused decreased mRNA level of canonical
WNT signaling target genes, OCT4 and Nanog. Addi-
tionally, performing ChIP assay identified that
KIAA1199 was essential for canonical WNT signaling
activation and a novel transcriptional factor for OCT4
and Nanog genes.
Conclusion: In this report, we identify that KIAA1199,
induced in pancreatic CSCs, is required for activation
of canonical WNT signaling. Further, as a novel tran-
scriptional factor for OCT4 and Nanog, KIAA1199
controls self-renewal and tumorigenesis of pancreatic
cancer cells. We can conclude that KIAA1199 involves
in maintaining stemness property in pancreatic CSCs,
through controlling canonical WNT signaling and tran-
scriptional activity.
APHPB-0578
OVEREXPRESSION OF PLATELET-
DERIVED GROWTH FACTOR
RECEPTOR ALPHA PROMOTES
TUMOR PROGRESSION AND
INDICATES POOR PROGNOSIS IN
HEPATOCELLULAR CARCINOMA
X. F. Zhang, T. Wei and Y. Lv
Department of Hepatobiliary Surgery, First Affiliated
Hospital of Medical College Xi’an Jiaotong University,
Xi’an, China
Objectives: Dysregulation of platelet-derived growth
factor receptor alpha (PDGFRa) has been documented
in various cancers. However, its role in hepatocellular
carcinoma (HCC) remains unknown.
Methods: We have examined that upregulation of
PDGFRa might be involved in hepatocarcinogenesis.
The mRNA and protein level of human HCC and adja-
cent liver tissues were determined and compared by
RT-PCR, western blot and immunohistochemistry. The
lentiviruses vector containing gene encoding full length
wildtype cDNA of PDGFRa and packaging plasmids.
The plasmid and control were both transfected into
Hep3B cells in vitro and nude mice in vivo, and prolif-
eration, migration and invasion of the hepatoma cells
were evaluated.
Results: The expression of PDGFRa was markedly
higher in human HCC compared to adjacent liver tis-
sues. Although PDGFRA mRNA was decreased in
HCC, but PDGF-A mRNA was dramatically increased
in HCC. Overexpression of PDGFRa was strongly cor-
related with microvessel density (MVD) of HCC
(p < 0.05), as well as macroscopic vascular invasion of
the tumors (p < 0.05). HCC patients with high
PDGFRa expression displayed a shorter overall sur-
vival and a higher recurrence rate than those with low
PDGFRa expression (p < 0.05, respectively). Addition-
ally, stable overexpression of PDGFRa in hepatoma
cells promoted cell proliferation, migration, invasion
and epithelial-mesenchymal transition in vitro. Simi-
larly, an in vivo assay showed that PDGFRa overex-
pression in hepatoma cells exhibited remarkably
tumorigenic potential in tumor size and weight in vivo,
which displayed markedly elevated MVD than controls.
Conclusion: Our study provided the evidence that
PDGFRa may serve as a candidate prognostic marker
and a novel therapeutic target for HCC.
APHPB-0596
EARY POSTOPERATIVE JEJUNAL
FEEDING AND MORBIDITY AFTER
PANCREATICODUODENECTOMY
X. F. Zhang, J. W. Lu and Y. Lv
Department of Hepatobiliary Surgery, First Affiliated
Hospital of Medical College Xi’an Jiaotong University,
Xi’an, China
Objectives: The indication and benefits of early postop-
erative jejunal feeding in patients undergoing pancreati-
coduodenectomy (PD) is still controversial. The aim of
the present study is to evaluate the impact of early
postoperative jejunal feeding (EPJF) on the complica-
tion incidence in patients undergoing pancreaticoduo-
denectomy (PD).
Methods: A retrospective review of 340 consecutive
patients undergoing classic PD (Whipple’s procedure)
from January 2009 to January 2013 were performed.
The patients were divided into EPJF group as those
who had been placed jejunal nutrition tube (n = 88),
and no planned feeding (NPF) group (n = 252). The
preoperative baseline characteristics, intraoperative
parameters, postoperative outcome were evaluated and
compared beween the two groups.
Results: No significant difference was shown in preop-
erative baseline characteristics (e.g. gender, age,
smoking, commorbidities such as cardiovascular dis-
ease, hypertension and diabetes mellitus, preoperative
biliary drainage, biochemical test), and neither was the
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intraoperative parameters (e.g. pancreatic and bile duct
diameter, tumor size, intraoperative bleeding and trans-
fusion, tumor pathology and surgical procedure).
Although most complications were not different
between the two groups, delayed gastric emptying
(DGE) and pulmonary infection were significantly
increased in EPJF group than NPF groups (15.9% vs.
6.7%, p = 0.016 and 10.3% vs. 3.6%, p = 0.024,
respectively). Additionally, compared to NPF, EPJF
seemed to be associated with delayed postoperative
passing flatus (p = 0.006), prolonged postoperative stay
(p = 0.055) and increased expenses (p = 0.008).
Conclusion: EPJF might be assciated with increased
incidence of DGE and pulmonary infection, as well as
delayed intestinal mobility recovery. EPJF should not
be routine in well-nourished patients underging PD at
low risk of nutrition-related complications.
Benign HPB Diseases
APHPB-0598
SYNBIOTICS IN SURGERY FOR
CHRONIC PANCREATITIS: ARE THEY
TRULY EFFECTIVE? A SINGLE BLIND
PROSPECTIVE RANDOMIZED
CONTROL TRIAL [CTRI/2013/06/003737]
M. Govindhan, R. Ashwin, R. Ravi, P. Senthilkumar,
R. kamalakannan, P. Anbalagan, B. Kesavan, S.
Jeswanth and P. Ravichandran
Surgical Gastroenterology & Liver Trasnplantation,
Government Stanley Medical College, Chennai, India
Objectives: In this study we aimed to determine the
impact of perioperative synbiotic therapy on postopera-
tive infectious complications, morbidity & mortality in
patients undergoing pancreatic surgery for chronic pan-
creatitis
Methods: A prospective monocentric randomized single
blind controlled trial was conducted in patients with
chronic calcific pancreatitis undergoing Frey’s proce-
dure.Group A received a specific synbiotic composition,
5 days prior and 10 days after the surgery.Group B
received a placebo. Primary study endpoint was the
occurrence of postoperative infection during the first
30 days. Secondary outcome measures were mortality,
length of hospital stay, days in intensive care unit and
duration of antibiotic therapy.From previous studies,
perioperative synbiotics reduce the proportion of
patients with infectious complications from 50% to
12%. Using this data, with alpha of 0.05 and power
80%, the calculated sample size was calculated as 35
patients for each group with a dropout rate of 10%.
Results: Of the 79 patients enrolled, 75 completed the
trial {Group A (n = 39) and Group B (n = 36)}. The
incidence of postoperative infective complications
(12.5% vs. 40% p < 0.05), duration of antibiotics ther-
apy (p < 0.05), and length of hospital stay (p < 0.05)
were significantly lower in the synbiotic group
Conclusion: This study shows synbiotics to be a prom-
ising therapy in significantly reducing septic complica-
tions, hospital stay and antibiotic requirement in
patients undergoing pancreatic surgery for chronic pan-
creatitis. Further basic and clinical research would clar-
ify the underlying mechanisms of their therapeutic
effect and define the appropriate conditions for use.[C-
TRI/2013/06/003737]
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APHPB-0608
HEPATOCELLULAR CARCINOMA
WITH BILE DUCT THROMBI IN NON
CIRRHOTIC LIVERS: IS AGGRESSIVE
SURGERY WORTHWHILE?
V. Sivasubramaniam, K. Balaraman, A. Pitchaimuthu,
S. Perumal, K. Rajendran, R. A. V. I. Ramasamy,
J. Sathyanesan, R. Palaniappan and M. Govindan
Surgical Gastroenterology, Government Stanley Medical
College, Chennai, India
Objectives: Obstructive jaundice due to bile duct
tumour thrombus (BDTT) is an unusual clinical entity
and an uncommon presenting feature of Hepatocellular
carcinoma (HCC). There is a paucity of studies which
have examined the outcome of hepatectomy in this sub-
set of patients. The objective of this study is to evaluate
the outcome of hepatectomy for HCC with obstructive
jaundice due to BDTT in non-cirrhotic livers
Methods: From 1997 to 2012, out of 426 HCC
patients, 39 with non fibrolamellar type HCC with
obstructive jaundice due to BDTT in non-cirrhotic liv-
ers, who underwent hepatectomy were analysed. In all
the patients, demographic, clinicopathological and
investigative data were noted
Results: The operative procedures included right hepa-
tectomy with thrombectomy through choledochotomy
and t tube drainage (n = 16), extended right hepatec-
tomy combined with extrahepatic bile duct excision
(n = 10), left hepatectomy (n = 9), extended left hepa-
tectomy (n = 2) and left lateral segmentectomy (n = 2).
Average blood loss and median operative time were
420 mL and 186 min respectively. The diameter of pri-
mary tumour ranged from 5 to 18 cm and the length of
the thrombi ranged between 3 and 7.5 cm. Postopera-
tive morbidity was 28.2% (n = 11) which included bile
leak in 4 patients.Two patients died of post hepatec-
tomy failure (mortality 5.1%).The 1, 3, 5 year survival
rates were 81.09%, 48%, 10.5% respectively with a
median survival of 28.6 months.
Conclusion: The mere presence of BDTT in HCC does
not indicate an advanced or inoperable lesion.When
technically feasible, formal hepatic resection is the pre-
ferred first-line treatment option.
APHPB-0614
A COMPARATIVE STUDY ON
INFLAMMATION-BASED PROGNOSTIC
SCORES IN PATIENTS WITH
PERIHILAR CHOLANGIOCARCINOMA
M. Okuno, T. Ebata, Y. Yokoyama, T. Igami, G.
Sugawara, T. Mizuno, J. Yamaguchi and M. Nagino
Division of Surgical Oncology Department of Surgery,
Nagoya University Graduate School of Medicine,
Nagoya, Japan
Objectives: There is increasing evidence that inflamma-
tion-based prognostic scores have prognostic value in
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several kinds of cancer. However, little is known in
perihilar cholangiocarcinoma. The aim of this study
was to evaluate whether inflammation-based prognostic
scores are truly associated with survival for patients
with perihilar cholangiocarcinoma.
Methods: Inflammation-based scores, including the
modified Glasgow Prognostic Score (mGPS), the Neu-
trophil Lymphocyte Ratio, the Platelet Lymphocyte
Ratio and the Prognostic Nutritional Index, were retro-
spectively evaluated in 534 patients who underwent
resection for perihilar cholangiocarcinoma. Blood sam-
ples taken 1–3 days before surgery after jaundice was
fully released with biliary drainage and cholangitis sub-
sided were used for scores.
Results: Of the 4 inflammation-based prognostic scores
evaluated, mGPS showed prognostic value, whereas the
remaining 3 systems did not. The survival for patients
with mGPS of 0 was significantly better than that for
patients with mGPS of 1 or 2 (41.7% vs. 26.3% at
5-year, p < 0.001). A mGPS of 1 or 2 was significantly
associated with higher incidence of preoperative cholan-
gitis, lymph node metastasis, and distant metastasis
(pM). Irrespective of absence (n = 442) or presence
(n = 92) of preoperative cholangitis, the survival for
patients with mGPS of 0 was significantly better than
that for patients with mGPS of 1 or 2. Multivariate
analysis revealed that mGPS, blood transfusion, histol-
ogy, curability (R status), pN, and pM were indepen-
dent prognostic factors.
Conclusion: mGPS is an independent prognostic factor
in resected perihilar cholangiocarcinoma, like other
solid cancers. This simple and inexpensive scoring sys-
tem may play an important role in refining patient
stratification and in predicting survival in the disease.
APHPB-0616
DOES RESECTING PYLORUS RING
DURING
PANCREATICODUODENECTOMY
IMPROVE SHORT AND LONG-TERM
OUTCOMES COMPARED WITH
PRESERVING PYLORUS RING? THE
RESULTS OF A PROPECTIVE
RANDOMIZED CONTROLLED TRIAL
M. Kawai, S. Hirono, K. Okada, M. Miyazawa,
A. Shimizu, Y. Kitahata, M. Ueno, S. Hayami,
S. Yamaguchi and H. Yamaue
Second Department of Surgery, Wakayama Medical
University, Wakayama, Japan
Objectives: To preserve pylorus ring with denervation
and devascularization after pylorus-preserving pancre-
atoduodenectomy (PpPD) may be a risk factor of DGE
after pancreaticoduodenectomy. We conducted this
study to confirm the hypothesis that pylorus-resecting
pancreatoduodenectomy (PrPD) reduces the incidence
of DGE compared to PpPD.
Methods: At Wakayama Medical University Hospital
(WMUH), 130 patients with pancreatic or periampul-
lary lesions were randomized to PpPD or toPrPD to
evaluate the short and long-term outcomes. Primary
endpoint is the incidence of DGE.
Results: Of 130 patients who were enrolled in this
study, 64 patients were randomized to PpPD and 66 to
PrPD. The overall incidence of DGE in this RCT was
10.8% (14 of 130 patients); the overall incidence of
DGE was significantly lower in PrPD (4.5%) than
PpPD (17.2%) (p = 0.0244). DGE was classified into
three categories proposed by the International Study
Group of Pancreatic Surgery. The proposed clinical
grading classified 11 cases of DGE in PpPD into grades
A (n = 6), B (n = 5), and C (n = 0), and one case in
PrPD into each of the three grades. In long-term out-
comes, weight loss > grade 2 (Common Terminology
Criteria for Adverse Events, Ver. 4.0) at 24 months
after surgery improved significantly in PrPD (16.2%)
compared with PpPD (42.2%) (p = 0.011). Nutritional
status and late postoperative complications were similar
between PpPD and PrPD.
Conclusion: This study clarified that PrPD can lead to
a significant reduction in the incidence of DGE com-
pared with PpPD. Moreover, PrPD offers similar long-
term outcomes with PpPD.
APHPB-0621
ASSESSING LIVER REMNANT
INTRAOPERATIVELY WITH
INDOCYANINE GREEN CLEARANCE
DURING VASCULAR EXCLUSION:
EARLY RESULTS WITH THE ALIIVE
TECHNIQUE
L. Lau, M. Nikfarjam, G. Starkey, M. A. Fink, R.
Jones, C. Christophi and V. Muralidharan
Surgery, Austin Health, Heidelberg, Vic., Australia
Objectives: The most significant risk following major
hepatectomy is post-hepatectomy liver failure second-
ary to insufficient liver remnant. This study reports the
early experience using indocyanine green (ICG) clear-
ance intraoperatively as a novel tool to assess the
actual functional liver remnant before vascular division.
Methods: Ten patients undergoing planned major liver
resection (hemihepatectomy or greater) were recruited.
Intraoperative ICG clearance was performed at various
time points: 1) Preoperatively 2) Under anaesthesia 3)
Inflow control 4) Inflow control following parenchymal
transection 5) During complete vascular exclusion. To
compare, all patients underwent routine CT volumetry.
Outcome measures were post-hepatectomy liver failure
and mortality.
Results: There were 3 patients who had post-hepatec-
tomy liver failure and one patient with subsequently
died. In the patient who died, ICG clearance during
vascular exclusion was significantly lower (7.1%/min
vs. mean 14.4  4.85%/min). The ALIIVE technique
was shown to potentially influence outcome in three
other patients. In two patients, poor intraoperative
ICG clearance lead to a conversion to volume manipu-
lation with subsequent uneventful staged resection. In a
third patient, confirmation of adequate liver remnant
during the ALIIVE step lead to completion of extended
hemihepatectomy without post-hepatectomy liver fail-
ure.
Conclusion: Intraoperative assessment of the future
liver remnant using ICG clearance is feasible and may
© 2015 The Authors
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be used as a safety check step during major liver resec-
tions. The ALIIVE technique allows for the direct
assessment of the liver remnant before the irreversible
step of vascular division. Further studies are required
to delineate the ideal cut-off level for this assessment.
Transplantation
APHPB-0623
DATA-MINING AND MACHINE-
LEARNING ALGORITHMS TO PREDICT
OUTCOMES FOR LIVER
TRANSPLANTATION
L. F. Lau1, Y. Kankanige2, J. Bailey2, B. Z.
Rubenstein2, M. A. Fink1, G. Starkey1, B. Z. Wang1,
C. Christophi1, R. Jones1 and V. Muralidharan1
1Surgery, Austin Health, Melbourne, Vic., Australia;
2Computing and Information Systems, University of
Melbourne, Melbourne, Vic., Australia
Objectives: Organ allocation for liver transplantation is
a delicate balance between the utility of a limited
resource and the risk of harming a recipient with an
unsuitable organ. Machine-learning algorithms can
detect complex interdependencies in large volumes of
data and can create predictive models specific to the
population from which the data set was derived. The
aim of this study is to train a computer algorithm for
outcome prediction at Victorian Liver Transplant Unit
(VLTU).
Methods: The VLTU database containing a compre-
hensive dataset of all 878 liver transplants performed
was used to establish a training and testing set. Three
models were constructed comprising of donor variables
(D), donor and recipient variables (DR), and donor,
recipient and operative variables (DROP). The outcome
parameters were primary non-function (PNF) and early
allograft dysfunction (EAD). To compare, donor risk
index (DRI) and MELD scores were used.
Results: Three models were trained to predict outcome
and were superior to conventional prognostic indices.
Model D predicted PNF and EAD with an area under
the receiver operating curve (AUROC) value of 0.87
and 0.75 respectively. Model DR had an AUROC of
0.91 and 0.81 for PNF and EAD while the values for
Model DROP were 0.92 and 0.83. By comparison,
DRI had an AUROC of 0.83 and 0.67.
Conclusion: Computer-based algorithms based on data-
mining and machine-learning algorithms are powerful
tools that can accurately predict outcome following
liver transplantation which is specific to VLTU. Accu-
rate outcome prediction may be useful during donor
organ assessment and to potentially optimize donor-
recipient matching.
Benign HPB Diseases
APHPB-0634
LACK OF EFFICACY OF
PREOPERATIVE DEXAMETHASONE
FOR POSTOPERATIVE NAUSEA AND
VOMITING AFTER LAPAROSCOPIC
CHOLECYSTECTOMY: A LARGE-
SCALE, MULTICENTER,
RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIAL IN
JAPAN (CSGO-HBP-002)
Y. Takeda1, M. Wakasugi2, M. Tori2, J. Shimizu3,
T. Noda4, T. Yamamoto5, S. Oshima6, Y. Morimoto7,
T. Asaoka8, H. Eguchi9, M. Mori9, Y. Doki9 and
H. Nagano9
1Department of Surgery, Kansai Rosai Hospital,
Amagasaki, Japan; 2Department of Surgery, Osaka
Police Hospital, Osaka, Japan; 3Department of Surgery,
Osaka Rosai Hospital, Sakai, Japan; 4Department of
Surgery, Toyonaka Municipal Hospital, Toyonaka,
Japan; 5Department of Surgery, Sakai Municipal
Hospital, Sakai, Japan; 6Department of Surgery, Minoh
City Hospital, Minoh, Japan; 7Department of Surgery,
Osaka Kosei-Nenkin Hospital, Osaka, Japan;
8Department of Surgery, Osaka National Hospital,
Osaka, Japan; 9Department of Surgery, Graduate School
of Medicine Osaka University, Suita, Japan
Objectives: Postoperative nausea and vomiting (PONV)
after laparoscopic cholecystectomy (LC) are distressing
side effect. The present multicenter, randomized, dou-
ble-blind, placebo-controlled large-scale trial was con-
ducted to investigate the safety and prophylactic
efficacy of preoperative dexamethasone for PONV in
patients undergoing uncomplicated LC in Japan.
Methods: From May 2010 to August 2012, a total of
270 patients were randomized to receive dexamethasone
8 mg (n = 136) or placebo (n = 134) intravenously just
before LC. Primary endpoint was degree of PONV and
antiemetic requirements within 24 h after LC. Second-
ary endpoints were postoperative complications, post-
operative hospital stay, and cost of hospital stay.
Results: Within 6 h after LC, 17% (23/136) of patients
in the dexamethasone group versus 24% (32/134) in the
placebo group reported nausea (p = 0.3). 5% (7/136)
vs. 7% (10/134) reported vomiting (p = 0.2). Metoclo-
pramide 10 mg was used 0.09  0.31 times vs.
0.14  0.35 times (p = 0.2). From 6 to 24 h, 10% (14/
136) vs. 13% (17/134) reported nausea (p = 0.5). 5%
(7/136) vs. 5% (7/134) reported vomiting (p = 0.8),
respectively. Metoclopramide was used 0.04  0.19
times vs. 0.03  0.17 times (p = 0.8). Postoperative
complications and postoperative hospital stay did not
differ significantly between two groups, but the cost of
hospital stay was higher in the dexamethasone group
(p < 0.05).
Conclusion: Preoperative dexamethasone did not
reduce PONV after LC. Dexamethasone did not
increase postoperative complications or postoperative
hospital stay, but it did increase the cost of hospital
stay. (UMIN000003841)
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